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Abstract 
Superparamagnetic iron oxide nanoparticles (SPION) are used clinically to improve 
the sensitivity of magnetic resonance imaging (MRI). A less exploited property of 
SPION is their ability to generate heat when subjected to an alternating magnetic 
field, a process called magnetic alternating current hyperthermia (MACH). 
Hyperthermia has been shown to be a cancer effective treatment modality in the clinic 
when given together with radio/chemotherapy. However, delivery of sufficient heat to 
damage tumours without harming healthy tissue remains challenging. The central 
hypothesis for this thesis is that MACH activated SPION can be used to generate 
hyperthermia in situ and therefore will have potential to achieve localised 
hyperthermic cancer treatments.  
 
The aim of the thesis was to evaluate the potential of SPION to deliver localised 
hyperthermia by: (1) Characterization and comparison of SPION to select a lead 
candidate for clinical application. (2) Developing conjugation methods to confer 
SPION with cancer-binding properties by attachment of single chain Fv antibodies 
(scFv). (3) Evaluating the localisation and heating potential in vivo. 
 
SPION were characterized with regard to their hydrodynamic diameter, core size, 
magnetic properties, atomic iron content and heating potential for hyperthermia 
application. Different chemistries were evaluated to functionalize the most promising 
candidate using shMFEm, an scFv targeting the carcinoembryonic antigen (CEA). A 
CEA-non-binding scFv variant, shNFEm, was used as a negative control. 
Functionality of the scFv-SPIONs was assessed using quartz crystal microbalance. In 
vivo heating potential of the SPION was tested in a xenograft tumour model in vivo, 
using bespoke MACH apparatus. 
 
The results established Ferucarbotran (FX), unformulated Resovist®, an MRI contrast 
agent, as the most suitable candidate for hyperthermia application. Cyanogen 
bromide chemistry was selected to functionalise Ferucarbotran with the scFvs 
shMFEm. The FX-scFv conjugates were purified and analysed. Functionality was 
confirmed by quartz crystal microbalance, enabling the first visualisation of the 
interaction between a SPION-scFv conjugate and cognate antigen in real-time.  The 
in vivo assessment of Ferucarbotran and the FX-scFv conjugates confirmed the in 
vitro heating potential of Ferucarbotran. In vivo analysis of heating showed that 
localised hyperthermia was achievable with intratumoral injection followed by MACH.  
Histological analysis of the tumours revealed an uneven distribution of particles within 
the tumours and an accumulation of the particles within the surrounding stroma 
indicating the future work should include study of innovative tumour delivery methods.  
 
These results support the hypothesis of a therapeutic potential for targeted magnetic 
nanoparticle hyperthermia and indicates the challenges that have be addressed to 
enable clinical application of this treatment modality. 
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  1 
Chapter 1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1 Introduction 
  2 
Nanoparticles, nanotubes, nanoclusters – ‘nano’ and nanotechnology are used 
prevalently, while their true meaning remains a mystery. Most definitions on the topic, 
found on the web, characterize nanotechnology by the study and control of 
phenomena and materials at length scales smaller than 100 nm.  In the first issue of 
Nature Nanotechnology, 13 scientists in the field were asked for their definition of 
nanotechnology and got very different responses (Theis, Parr et al. 2006). Even 
though there might not be a consensus yet with regard to nanotechnology, there 
already is a definition for the sub-discipline of nanomedicine – The European Science 
Foundation in 2004 defined this as the following:  
 
“Nanomedicine is the science and technology of nanometre size scale complex 
systems, consisting of at least two components, one of which being the active 
ingredient… In this context, nanoscale should be taken to include active components 
or objects in the size range from one nanometre to hundreds of nanometres.” (ESF 
2004) 
 
Following this definition, nanoparticles are small entities between 1 and 1000 nm, 
varying in composition, shape and effect, dependent on their use. Nanoparticles can 
be synthesized within a narrow size distribution and specifically ‘tuned’ to meet the 
requirements of various applications.  
 
In this thesis, the focus was on magnetic nanoparticles consisting of iron oxide cores 
surrounded by carbohydrates, such as dextran and it’s derivatives or starch, similar to 
the ones already used in the clinic as contrast agents for magnetic resonance 
imaging (Reimer and Balzer 2003).  
 
Even though magnetic iron oxide nanoparticles are used clinically, targeting them to 
specific tissues remains a challenge. Therefore, the aims of this thesis were to 
identify suitable commercial nanoparticles for hyperthermia application, determine 
appropriate conjugation chemistry to functionalise them with scFv antibody fragments 
to enable targeting, purify and verify functionality of the nanoparticle-scFv conjugates, 
as well as evaluate their therapeutic potential in vivo. 
 
This chapter provides the physical background for this thesis, exploring different 
biomedical applications of magnetic nanoparticles, as well as the role of hyperthermia 
and its need for a more targeted approach in cancer therapy. 
 
  3 
1.1 Magnetic nanoparticles 
When materials are taken to the ‘nanoscale’ their properties change; magnetite, 
Fe3O4, in the form of magnetic iron oxide nanoparticles loses it its magnetic poles and 
splits into single magnetic magnetic moments with different magnetisation directions 
giving rise to different magnetic phenomena, such as paramagnetism, 
superparamagnetism or ferromagnetism (Pankhurst, Connolly et al. 2003; Morup 
2010). 
 
1.1.1 Basic Concepts 
The origin of magnetism lies in the orbital and spin motions of electrons and how 
electrons interact with each other. A material’s magnetisation strength depends on 
whether there is collective interaction of these electrons or not and can further be 
influenced by the atomic structure and also the temperature (Pankhurst, Connolly et 
al. 2003).  
 
The most common form of magnetism is diamagnetism, as it is a fundamental 
property of all matter. It is usually very weak and caused by the non-cooperative 
behavior of orbiting electrons, when a magnetic field is applied. As all orbitals are 
filled with paired electrons, diamagnetic materials have no net magnetic moment and 
therefore do not appear magnetic. (Cullity 2008) 
 
Paramagnetism occurs in materials, such as iron, which have a net magnetic moment 
due to unpaired electrons in partially filled orbitals. So, when subjected to a magnetic 
field, the magnetic moments in the material align with the direction of the field, 
resulting in a net positive magnetization and positive susceptibility. However, since 
thermal energy has a randomization effect in paramagnetic material, when the 
magnetic field is withdrawn there is no net magnetization. (Pankhurst, Connolly et al. 
2003; Cullity 2008) 
 
In ferromagnetism, there is a strong exchange interaction between the atomic 
moments, which results in a large net magnetization even in the absence of a 
magnetic field. However, in contrast to what the name suggests, this phenomenon is 
not limited to iron, but also arises in nickel, cobalt and many of their alloys.  When 
ferromagnetic particles are small enough (below about 20 nm), the magnetization flips 
randomly under thermal influence resulting in superparamagnetism. 
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Once the field is withdrawn the magnetic moments quickly ‘relax’. The time that this 
event takes is referred to as relaxation time τ (Pankhurst, Connolly et al. 2003; Cullity 
2008) and is described with the following equation:  
  Equation 1.1 
where K is the anisotropy energy density, V is the particle volume and kBT, the 
thermal energy, Boltzmann constant kB (1.38 x 10-23 J K-1) multiplied by  
the absolute temperature T (Pankhurst, Connolly et al. 2003). 
 
Superparamagnetic behaviour is strongly size dependent and in magnetite observed 
at sizes <20 nm hydrodynamic diameter (Pankhurst, Connolly et al. 2003; Hofmann-
Amtenbrink 2009) and a core size <5 nm (Krishnan 2010). 
 
As previously stated, thermal energy aims to randomize particles, where a magnetic 
field applies a torque on the particles to align with the field. While the thermal energy 
is the same for all particles, the magnetic torque is smaller for smaller particles. This 
behavior of the nanoparticles is described in the Langevin function:  
  Equation 1.2 
 
 Equation 1.3 
where µ0 is the permeability of free space (4π x 10-7 N A-2), m is the dipole moment, H 
the magnetic field strength, kB is the Boltzmann constant and T the absolute 
temperature. (Rosensweig 1997)  
 
These unique behaviours of magnetic nanoparticles have given rise to a number of 
biomedical applications. 
 
1.1.2 Biomedical Applications 
Biomedical applications of magnetic particles can be divided in four main categories: 
imaging, drug delivery, gene transfection and hyperthermia 
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1.1.2.1 Magnetic Resonance Imaging (MRI) 
The best know application of magnetic nanoparticles is MRI.  It exploits the small 
magnetic moment on a proton, such as the hydrogen nuclei, and its large number  
[6.6 x 1019/mm3 water (Pankhurst, Connolly et al. 2003)] present within the human 
body. When subjected to a static field, only a tiny fraction of protons will align in 
parallel to the field applied. However since there are so many, this response can be 
measured.  This is achieved through an alternating magnetic field set at the frequency 
to flip the magnetic moment of the proton. This field is orientated perpendicular to 
direction of the static field and applied in pulses, to allow for just enough time to 
capture the re-alignment of the spins with the static field. (Lepage 2004)  
 
There are two types of relaxation times: longitudinal relaxation, T1, involving the 
proton releasing absorbed energy to the surrounding tissue and transverse relaxation, 
T2, involving the exchange of energy between spinning protons (Pankhurst, Connolly 
et al. 2003).  These relaxation times can be reduced by the use of magnetic contrast 
agents (Lin and Brown 2007), such as Resovist® (Reimer and Balzer 2003).  
 
Superparamagnetic nanoparticles are magnetically saturated in a static field and 
thereby generating a dipolar field, causing a shortened relaxation time. (Pankhurst, 
Connolly et al. 2003) 
 
The most commonly used MRI contrast agents in the clinic currently include 
paramagnetic gadolinium complexes Magnevist®, Gadovist® (Pintaske, Martirosian et 
al. 2006) or Primovist™ (Hammerstingl, Huppertz et al. 2008) to improve T1 
relaxation, and ultrasmall superparamagnetic iron oxide nanoparticles (USPIO), such 
as Supravist™ (Simon, von Vopelius-Feldt et al. 2006), to improve T2 relaxation.  
 
One of the most exciting developments in MRI contrast agents is magnetic block 
ionomer clusters (MBIClusters). Carroll et al showed that magnetite nanoparticles 
coated with copolyethers, when “clustered” increased their T2 relaxivities and were 
1.7 times better than commercial contrast agent Feridex® (Carroll, Huffstetler et al. 
2011). Recently they went one step further and demonstrated that the model drug 
gentamicin, an antibiotic, could be incorporated in the clusters without affecting the 
high MRI sensitivity of the MBIClusters; combining imaging with drug delivery 
(Pothayee 2013). 
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1.1.2.2 Magnetic Particle Imaging  
In 2005, Gleich and Weizenecker, presented a completely new imaging modality – 
magnetic particle imaging (MPI). Hereby an alternating magnetic field is applied to 
nanoparticles resulting in a non-linear magnetization. A static field is superimposed 
on the oscillating field, so the nanoparticles remain in their maximum magnetization. 
However, this static field is provided by two antiparallel coils generating a field free 
point (FFP) enabling the detection of the changing magnetization (harmonics) caused 
by the alternating magnetic field (Gleich and Weizenecker 2005).  
 
In their first experiments, Resovist® was used, but only a small fraction of particles 
demonstrated the desired harmonics calling for specifically designed nanoparticles 
(Biederer, Knopp et al. 2009). Since then first in vivo studies have been performed 
(Weizenecker, Gleich et al. 2009), new scanners developed (Sattel, Knopp et al. 
2009) and currently the focus lies on improving particle designs (Eberbeck, Wiekhorst 
et al. 2011; Ferguson, Minard et al. 2011) and reconstruction (Goodwill and Conolly 
2011; Lampe, Bassoy et al. 2012). 
 
1.1.2.3 Implant-assisted Magnetic Targeting 
One of the biggest challenges in coronary disease is in-stent thrombosis. Therefore 
Kempe and Kempe (Kempe and Kempe 2010) proposed the combination of a 
magnetisable stent with magnetic nanoparticles carrying the tissue plasminogen 
activator (tPA) for thrombolysis and a static magnetic field. The static magnetic field 
induces magnetic field gradients within the stent and enables targeting of the tPA 
loaded nanoparticles, in order to break down blood clots. First results from in vivo pig 
experiments are promising. 
 
1.1.2.4 Magnetic Pushing 
Permanent or electromagnets attract magnetic particles and so the majority of 
magnetic systems are based on this fact. However, in order to direct magnetic 
nanoparticles to the inner ear or the back of the eye, incredibly strong magnets would 
have to be used due to the exponential decay of magnetic field strength with distance 
from the magnet. Therefore, Sarwar et al. developed a magnetic system, consisting of 
just two permanent magnets arranged at an angle (Fig. 1.1), to push nanoparticles 
and enable treatment of inner-ear diseases, such as tinnitus (Sarwar, Nemirovski et 
al. 2012; Sarwar, Lee et al. 2013).  
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Fig. 1.1 Two permanent magnets can push particles away. A) Schematic field lines around a 
single magnet. B) Two magnets oriented, so that their polarity is reversed. C) When these two 
magnets are correctly overlaid their magnetic fields add to exactly cancel at the node point C 
(big black dot), but they do not cancel around that point (purple ring) thus forces go outward 
enabling pushing. (Sarwar, Lee et al. 2013) [Reprinted, with permission from Sarwar, Lee et 
al., Magnetic injection of nanoparticles into rat inner ears at a human head working distance, 
IEEE Transactions on Magnetics, 2013] 
 
1.1.2.5 Magnetofection 
Another important biomedical application of magnetic nanoparticles is magnetic 
transfection for gene delivery, also known as magnetofection. Nucleic acids and 
cationic lipids or polymers are associated with superparamagnetic nanoparticles and 
accumulated on the surface of target cells by applying a magnetic field (Plank, 
Schillinger et al. 2003). This set-up leads to substantially improved in vitro 
transfection efficiencies compared with nonmagnetic gene vectors (Mykhaylyk, 
Antequera et al. 2007), which was even further enhanced by mechanical stimulation 
through the use of oscillating magnet arrays and pulsed electromagnets (McBain, 
Griesenbach et al. 2008).  
 
1.1.2.6 Magnetic Microbubbles for Drug Delivery 
A different approach using magnetic nanoparticles for gene delivery combines 
magnetofection with ultrasound and nanoparticle loaded microbubbles (Stride, Porter 
et al. 2009). However, this technique is not only interesting for transfection, but also 
drug delivery and imaging.  
 
Bubbles are interesting delivery vehicles. Depending on the design, nanoparticles or 
drugs can be incorporated in the coating or loaded within the bubble itself, while 
depending on the acustic field applied different physical effects, such as microjetting 
B A C 
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may improve drug delivery opening an array of possibilities (Stride and Coussios 
2010; Owen, Pankhurst et al. 2012). 
 
1.1.2.7 Magnetic Actuation 
Magnetic manipulation of cell surface receptors is a relatively new procedure of 
interest not only for tissue engineering, but also therapeutic applications.  There are 
different approaches for magnetic actuation, as shown in Figure 1.2.  In general 
nanoparticles are conjugated with targeting moieties specific to certain cell surface 
proteins. The cells are incubated with the nanoparticle conjugates before actuation is 
initiated through the application of magnetic field, such as provided by a magnetic 
needle.  Magnetic actuation can enable transduction either through twisting of the 
particles by applying a magnetic torque (magnetic twisting cytometry); open ion 
channels through pulling on the membrane (mechanosensitive ion-channel 
activation); manipulating a channel with a nanoparticle directly (targeted ion-channel 
activation) or by clustering receptors. (Dobson 2008)   
 
 
Fig. 1.2 Different types of magnetic actuation: Magnetic twisting cytometry (A); 
Mechanosensitive ion-channel activation (B); Targeted ion-channel activation (C); Receptor 
clustering (D) (Dobson 2008) [Reprinted, with permission from Dobson, Remote control of 
cellular behaviour with magnetic nanoparticles, Nature Nanotechnology, 2008] 
 
A B 
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Mannix et al. presented another mechanism involving receptor clustering (Mannix, 
Kumar et al. 2008), whereby superparamagnetic nanoparticles were coated with 
monovalent ligands and bound to transmembrane receptors. The presence of a 
magnetic field causes clustering between nanoparticles, but also between the bound 
receptors, directly inducing a signalling cascade.  Cho et al. adapted this idea in vivo 
and recently demonstrated initiation of apoptosis in the tail region of zebrafish 
embryo, by targeting and clustering the TNF-related apoptosis inducing ligand 
(TRAIL) (Cho, Lee et al. 2012).  
 
 
1.2 Hyperthermia in Cancer Therapy 
Magnetic fluid hyperthermia, another biomedical application of magnetic 
nanoparticles, is of particular interest in cancer therapy, as other forms of 
hyperthermia are already in use. 
 
1.2.1 Hyperthermia in Cancer Therapy 
In the literature conventional hyperthermia refers to temperatures used between 40 
and 44 °C, while thermal ablation discusses temperatures above 50 °C (van der Zee 
2002; Chichel 2007). 
 
The rational behind using hyperthermia in cancer therapy is that cells are more 
susceptible to temperatures between 40 to 44 °C under low pH and low oxygen 
conditions, which can be found in necrotic regions of tumours, due to poor 
vascularisation and blood supply (Otte 1988).  These cells can enter the G0 phase of 
the cell cycle rendering them resistant to most cytostatic drugs, while cells in the S 
phase are mostly resistant to radiation, but also most susceptible to heat (Hildebrandt 
and Wust 2007). Therefore hyperthermia has a cytotoxic effect on radioresistant cells 
at temperatures above 42 °C. While at lower temperatures between 39.5 °C and 40.5 
°C, the heating improves vascularisation increasing the oxygen supply and thus 
sensitizes them to radiation. (van der Zee 2002)  
 
In chemotherapy depending on the temperature and length of the treatment 
hyperthermia has the potential to enhance the blood supply within the tumour and 
enabling improved delivery of cytostatic drugs (Otte 1988; Hildebrandt and Wust 
2007). 
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1.2.2 Clinical Hyperthermia  
The parts of the body that receive hyperthermic treatment, such as whole-body, 
partial and local hyperthermia, distinguish the different kinds of hyperthermia used in 
the clinic. 
Whole-body hyperthermia aims to achieve a body temperature of 41.8 to 42 °C by 
using wax baths, thermal chambers, hot water blankets, infrared radiators or 
extracorporeal circulation in order to treat metastatic cancers such as melanoma 
(Otte 1988; van der Zee 2002; Wust, Hildebrandt et al. 2002). 
 
Partial or regional hyperthermia for deep seated tumours or locally advanced cancer 
is often achieved through isolated perfusion or the use of external applicators, 
antennas emitting microwave or radiofrequencies. The main advantage of this 
approach over whole-body hyperthermia is less systemic side effects, however burns 
and other side effects are reported (van der Zee, Gonzalez et al. 2000). 
 
Local hyperthermia, the most frequently used, originally was distinguished by the 
method inducing the heat, like microwave (0.3 - 6 MHz), ultrasound (50 - 2450 MHz) 
or radiofrequency hyperthermia (Otte 1988). More recent hyperthermia treatments 
involving nanoparticles include last near-infrared photothermal therapy, 
radiofrequency ablation and magnetic nanoparticle hyperthermia (Day, Morton et al. 
2009).  
 
1.2.2.1 NIR Photothermal Therapy 
In near-infrared photothermal therapy gold-silica nanoshells are injected 
intravenously. Due to the leaky vasculature of the tumour they tend to accumulate in 
the tumour, where they are excited with a near infrared light source. The absorption of 
this near infrared light, between 700 nm and 900 nm, leads to generation of heat and 
irreversible tissue damage. (Gobin, Lee et al. 2007) 
 
1.2.2.2 Radiofrequency Ablation 
Radiofrequency ablation on the contrary relies on the administration of radiofrequency 
irradiation. Therefore an electrode is inserted into the tumour to apply a 
radiofrequency current, which leads to frictional heating (Curley 2001). The 
conductivity of gold nanoparticles and single-walled carbon nanotubes allow more 
efficient and non-invasive radiofrequency heating (Gannon, Cherukuri et al. 2007; 
Gannon, Patra et al. 2008).  
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1.3 Magnetic Nanoparticle Hyperthermia 
Magnetic nanoparticle or magnetic fluid hyperthermia was first proposed in 1957 by 
Gilchrist et al. as a new method to destroy cancer in lymph nodes by injecting them 
with ‘particulate matter’ of γ-Fe2O3 before applying an alternating magnetic field 
(Gilchrist, Medal et al. 1957) 
 
Even though this concept has been known, it was not until the early 1990s that it was 
rediscovered and explored in combination with other treatments. Only recently, the 
European Medicines Agency (EMA) approved magnetic nanoparticle hyperthermia for 
the treatment of glioblastoma multiforme (Maier-Hauff, Ulrich et al. 2011). While 
approval by the US Food Drug Administration (FDA) is still pending, there are several 
clinical trials exploring magnetic fluid hyperthermia for several different cancers, such 
as glioblastoma, prostate and pancreatic cancer (Johannsen, Gneveckow et al. 2007; 
Johannsen, Gneveckow et al. 2007; van Landeghem, Maier-Hauff et al. 2009; Maier-
Hauff, Ulrich et al. 2011). 
 
1.3.1 Magnetic Fields, Hysteresis and Relaxation Times 
As magnetic nanoparticles are placed in an alternating magnetic field, they heat due 
to different magnetic losses within the particle: Hysteresis, Néel relaxation and 
Brownian motion (Hergt, Dutz et al. 2006). Eddy current induced heating, due to the 
size of the nanoparticles, is negligible (Rosensweig 2002).  
 
1.3.1.1 Hysteresis 
When a magnetic material is subjected to a magnetic field, each magnetic moments 
in the material contributes to the overall response also known as magnetic induction 
B, which is given by  
 Equation 1.4 
where the magnetic field intensity H, generated in the centre of a current loop, is 
measured by A m-1; the magnetization (intensity) M expressed as M = m/V is the 
magnetic moment m per unit volume V, which, like H, is also measured by A m-1 and 
the permeability of free space µ0. (Rosensweig 2002; Pankhurst, Connolly et al. 2003) 
 
€ 
B = µ0(H + M)
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The magnetization M can also be expressed as  
 Equation 1.5 
where χ is the dimensionless susceptibility, which is not only dependent on M and H 
(as indicated in the function above, but also on temperature). However, H accounts 
for the typical sigmoidal shape of the MH curve.  
 
If a ferro- or ferrimagnetic material is placed in a magnetic field the magnetic 
moments within the material align with the direction of the applied field. When the 
magnetic field is withdrawn, some magnetic moments due the crystalline anisotropy 
will still retain this alignment for an indefinite amount of time; the magnetization is 
irreversible. Only the application of magnetic field in the reversed direction will lead to 
a partial demagnetization. Therefore a typical MH curve for this kind of material will 
result in a more open hysteresis loop (Pankhurst, Connolly et al. 2003).  
 
1.3.1.2 Néel Relaxation  
In small magnetic nanoparticles (below 20 nm) the magnetic moments flip randomly 
under the influence of temperature. The time it takes for a nanoparticle system to flip 
the magnetic moment across the anisotropy barrier is given by the  
Néel relaxation time τN  
 Equation 1.6 
where τ0 is the attempt time (τ0 ≈ 10-9 sec), ΔE is the anisotropy energy and kBT is the 
thermal energy: the product of the Boltzmann constant kB (1.38 x 10-23 J K-1) and 
absolute temperature T (Hergt, Dutz et al. 2006).  The anisotropy energy ΔE can also 
be described as anisotropy energy density K times the particle V, this is also the 
reason why ΔE and therefore the Néel relaxation effect gets more and more important 
as the particle size decreases and superparamagnetism arises (Pankhurst, Connolly 
et al. 2003). 
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1.3.1.3 Brownian Motion 
If the magnetic moment is fixed to the easy axis within the particle, when placed in a 
magnetic field, not only the moment aligns with the direction of the field, but also the 
whole particle rotates, commonly referred to as Brownian motion 
  Equation 1.7 
where η is the viscosity coefficient of the fluid surrounding the particle, VH is the 
hydrodynamic volume or diameter and the thermal energy kBT.	   (Rosensweig 2002; 
Hergt, Hiergeist et al. 2004) 
	  
Therefore the Brownian motion describes the actual rotation of the particle in the fluid 
in contrast to Néel relaxation the flipping of the magnetic moment within the particle 
without actual movement of the nanoparticle. 
 
1.3.1.4 Effective Relaxation 
During hyperthermia in a magnetic fluid with a narrow size distribution (PdI <0.1) the 
faster relaxation mechanism (Néel relaxation or Brownian motion) will dominate and 
therefore the effective relaxation time can be described by (Hergt, Andra et al. 1998) 
  Equation 1.8 
Since most magnetic nanoparticle suspensions have a normal distribution of sizes, 
both Néel relaxation and Brownian motion will contribute to the heating of the fluid in 
the presence of an alternating magnetic field leading to the effective relaxation time 
(Rosensweig 2002). 
  Equation 1.9 
 
The overall power dissipation of particle is described by 
  Equation 1.10 
where µ0 is the permeability of free space, χ” is the imaginary susceptibility, f the 
frequency and H field strength of the applied field (Rosensweig 2002; Kallumadil, 
Tada et al. 2009). 
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1.3.1.5 Specific Absorption Rate (SAR) and Intrinsic Loss Power (ILP) 
In order to compare heating rates of different magnetic nanoparticles, in the literature 
it is often referred to the specific loss power (SLP) or specific absorption rate (SAR) 
given in W/g (Ma, Wu et al. 2004; Hergt, Dutz et al. 2006). 
 Equation 1.11 
where c is the heat capacity of water, msample is the mass of the sample, mironoxide is the 
mass of iron oxide in the sample measured magnetically and ΔT/Δt is the slope of the 
time dependent heating curve (Krishnan 2010) 
 
However, instead of reflecting the heating potential of a MNP suspension, the SAR 
value depends mostly on external factors such as frequency and strengths of the 
magnetic field applied and therefore will vary for the same sample in different 
magnetic fields.  
 
So in 2009, Kallumadil et al (Kallumadil, Tada et al. 2009) introduced the concept of 
intrinsic loss power (ILP), where SAR is normalized against frequency f and magnetic 
field strength H, which allows the direct comparison of heating potential of MNPs, by 
different groups using different magnetic field parameters. As the units for field 
strength H and frequency f are kA/m and kHz, ILP is measured in nH m2 kg-1. 
  Equation 1.12 
 
 
1.4 Need for Targeting 
A major issue with non-targeted treatment modalities is their specificity. Systemic 
injection of drugs often leads to unwanted side effects and limits their efficacy. 
Therefore, over a hundred years ago Paul Ehrlich introduced the ‘magic bullet 
concept’, proposing drugs moving directly to their intended cell-structural target. 
(Strebhardt and Ullrich 2008) 
 
In magnetic nanoparticle hyperthermia the particles are either injected systemically or 
directly into the tumour, where the particles accumulate due to the leaky vasculature. 
This passive targeting approach however proves not to be very effective, as particles 
are rapidly cleared from the system, by uptake in reticuloendothelial system and 
€ 
SAR = c msamplemironoxide
ΔT
Δt
€ 
ILP = SARH 2 f
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consequently in liver and spleen, which makes them a good contrast in magnet 
resonance imaging (MRI) for the diagnosis of liver tumours (Reimer and Balzer 2003). 
 
Therefore, in the last years researchers focused on improving the stealth of the 
coating with polymers, such as polyethylene glycol (PEG) (Gref, Luck et al. 2000) 
(Khalid, Simard et al. 2006), but also to target nanoparticles by the attachment of 
antibodies (Kirpotin, Drummond et al. 2006). 
 
1.4.1 Antibodies 
Antibodies, also known as human immunoglobulins (IgG, IgM, IgA, IgE) are highly 
specific targeting molecules and the first line of defense of our immune system.  The 
main serum antibody, the Y-shaped IgG (see Fig. 1.3) consists of two heavy and two 
light peptide chains, connected by disulphide bridges, together forming two antigen-
binding arms with the Fc region for effector function (Edelman 1973). The variable 
region, Fv, contains the complementary determining regions (CDR), which define the 
binding specificity of the antibody.  
 
First identified by Kabat and Tiselius (Tiselius and Kabat 1939) in the late 1930s, it 
was not until the development of the hybridoma technology that this field of antibodies 
gained momentum.  By fusing mouse B cell clones with immortalised mouse 
myeloma cells generating hybridomas, Köhler and Milstein were the first to enable 
mass production of specific monoclonal antibodies (Kohler and Milstein 1975). 
However, due to their murine origin, these antibodies induced human anti-mouse 
antibodies (HAMA), when used in humans (Tjandra, Ramadi et al. 1990). This 
resulted in a shortened blood half life and lower treatment efficacy. 
 
In order to overcome the immunogenicity of the murine antibodies, chimeric and 
humanised antibodies were developed. So, as to generate a chimeric antibody, the 
entire murine variable regions were fused into the human IgG (Adams and Weiner 
2005), while for the humanised antibody only the CDR were engineered into the 
human IgG (Jones, Dear et al. 1986).  These developments gave rise to first 
monoclonal antibodies to receive FDA approval: Rituximab (Rituxan), a chimeric 
antibody for the treatment of B-cell non-Hodgkin’s lymphoma and Trastuzumab 
(Herceptin), a humanised anti-HER2/neu antibody for breast cancer therapy (Adams 
and Weiner 2005) – marking a major milestone in cancer therapy (Chabner and 
Roberts 2005).  
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Fig. 1.3 Schematic structure of human IgG and derived antibody fragments (Kozissnik 
2012) [Reprinted, with permission from, Thanh, Magnetic Nanoparticles: From Fabrication to 
Clinical Applications, CRC Press, 2012] 
 
Consequently, to improve their therapeutic potential antibodies were linked to 
cytotoxic drugs, toxins or radionucleotides (Scott, Wolchok et al. 2012). Additionally in 
order to enhance penetration and tumour concentration smaller formats, such as 
shown in Figure 1.3, are under investigation with the most prominent being the scFv 
(Holliger and Hudson 2005).  
 
1.4.2 Single chain Fv (scFv)  
The single chain Fv antibody fragment, with a size of 28 kDa, consists of one variable 
heavy chain and one variable light chain, connected only through a flexible 
polypeptide linker to prevent dissociation (Holliger and Hudson 2005). The small size 
allows scFvs to penetrate tumours much quicker than whole IgG, as scFv are easily 
selected for almost any target using page display and recombinant antibody 
technology (Ahmad, Yeap et al. 2012) and generated in high quantities through in 
non-mammalian expression systems, such as yeast, Pichia pastoris (Tolner, Smith et 
al. 2006). This not only makes them a prime target for potential clinical application, 
but also the moiety of choice for the targeting of magnetic nanoparticles in this thesis. 
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1.4.3 Functionalisation Chemistries 
In order to attach scFv or other molecules to magnetic nanoparticles effective 
functionalisation chemistry has to be formulated. This is dependent on both, the 
functional groups available on the surface of the nanoparticles and the accessible 
groups present within the scFv.  In proteins, the functional groups are typically amines 
provided by lysines, while the functional groups available on the nanoparticles are 
dependent on the polymer coating (Kozissnik 2012), such as carboxydextran shown 
in Figure 1.4. 
 
Fig. 1.4 The chemical structure of carboxydextran offers two options for attachment, multiple 
hydroxyl groups and one carboxyl group. 
 
1.4.3.1 Carbodiimide Coupling 
The most prevalent conjugation chemistry is carbodiimide coupling of a carboxylic 
acid to an amine using 1-ethyl-3-(dimethylaminopropyl)carbodiimide (EDC) in 
combination with N-hydroxysuccinimide (NHS). Even though an amide bond can be 
formed directly between carboxyl and amine group, NHS is added to enhance the 
reaction efficiency by stabilising the O-acylisourea intermediate through the formation 
of a succinimide ester (Hermanson 2008) as demonstrated in Figure 1.5.  
 
Fig. 1.5 Schematic representation of carbodiimide coupling of a carboxylic acid residue to an 
amine using EDC and NHS (Thanh and Green 2010) [Reprinted, with permission from, Thanh 
and Green, Functionalisation of nanoparticles for biomedical applications, NanoToday, 2010] 
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1.4.3.2 Cyanogen Bromide Conjugation 
Since carboxydextran provides numerous hydroxyl groups cyanogen bromide 
conjugation can be used instead of the carbodiimide coupling. 
 
Fig. 1.6 Schematic representation of cyanogen bromide conjugation of an amine to a hydroxyl 
using cyanogen bromide (CNBr) to first form a cyanate ester and consequently an isourea 
bond with the ligand (Kozissnik 2012) [Reprinted, with permission from, Thanh, Magnetic 
Nanoparticles: From Fabrication to Clinical Applications, CRC Press, 2012] 
 
The reaction occurs in two steps (see Fig. 1.6): First the nucleophilic hydroxyl group 
attacks the electron deficient carbon and reduces the bromine to hydrogen bromide. 
In a second step a nucleophilic addition of the amine to the electron-deficient cyanide 
group forms an isourea bond. (Kozissnik 2012) 
 
1.4.3.3 Further Challenges 
Even though the field of magnetic nanoparticle hyperthermia has seen important 
advances in recent years, achieving a sufficient concentration within the target tumour 
still remains as a challenge. Many in vivo studies in the past relied on direct local 
delivery (Jordan, Scholz et al. 1997, Johannsen, Gneveckow et al. 2007) rather than 
systemic delivery.  
 
Direct injection was also the route of administration used in the first clinical trial with 
magnetic nanoparticle hyperthermia for the treatment of glioblastoma multiforme 
(Maier-Hauff, Ulrich et al. 2011).  
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In this study, under anaesthesia, the patients were injected with semi-passively 
targeted aminosilane coated iron oxide nanoparticles (0.28 ml magnetic fluid per cm3 
of tumour volume) and treated with thermotherapy for 1 hr in six semi-weekly 
sessions. Additionally, the patients received radiotherapy (30 Gy in 5 x 2 Gy/week) 
before or after the intratumoural therapy sessions.  
 
The results showed an improvement in overall survival of the patients and lead to the 
clinical approval of magnetic nanoparticle hyperthermia for the treatment of 
glioblastoma multiforme by the European Medicines Agency (EMA).  
 
Although this study represents an important milestone, it remains quite controversial. 
Soon after its results were published in the Journal of Neurooncology, a ‘letter to the 
editor’ scrutinised the set-up of the clinical trial, as the patients were not randomised 
and had received different courses of treatment for their cancer before being admitted 
into this clinical study. Additionally, the authors of the article also critised that prior to 
treatment, for safety reasons, all dental fillings, crowns and implants of the patients 
had to be removed, not aiding the quality of life perspective of the patient. (Weller, 
Wick 2011) 
 
In order to move magnetic nanoparticle hyperthermia forward, nanoparticles have to 
be actively targeted through the attachment of a targeting moiety, such as scFv 
antibody fragments, potentially limiting the side effects and therefore improving the 
quality of life of cancer patients. 
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1.5 Research Aims 
The central hypothesis for this thesis is that antibody targeted superparamagnetic iron 
oxide nanoparticles subjected to an alternating magnetic field can be used to 
generate hyperthermia in situ and therefore have the potential to achieve localised 
hyperthermic cancer treatments.  
 
Therefore, Chapter 2 outlines the key methods and materials used in this thesis. This 
includes the selection of appropriate techniques for the characterisation of the 
nanoparticles, as well as the scFv antibody fragments, the functionalisation of the 
nanoparticles with the scFv antibody fragments, the purification and characterisation 
of the SPION-scFv conjugates and the antibody targeted magnetic nanoparticle 
hyperthermia in vivo. 
 
Chapter 3 provides a detailed property analysis of different commercial nanoparticles 
determining characteristics, such as hydrodynamic diameter, zeta potential, core 
structure, atomic iron content and heating potential in order to identify the best 
nanoparticle for hyperthermia application. 
 
Chapter 4 investigates the functionalisation of this nanoparticle with scFv antibody 
fragments evaluating different conjugation chemistries and purification techniques. 
Another focus in this chapter is the characterisation and verification of the 
functionality of the SPION-scFv conjugates. 
 
Chapter 5 explores the therapeutic potential of the SPION-scFv conjugates in vivo. 
 
Chapter 6 provides a detailed discussion of the results presented in the preceeding 
chapters, while Chapter 7 focuses on the challenges ahead. 
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Chapter 2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2 Materials and Methods 
  22 
2.1 Introduction 
The aim of this thesis was to investigate the potential of magnetic nanoparticles 
(MNP) to deliver targeted hyperthermia for the treatment of tumours. The work 
described in this chapter was to find suitable commercially available MNP candidates 
for hyperthermia, as well as appropriate techniques for the characterisation, 
functionalisation and hyperthermia application in vivo. 
 
In order to ensure biocompatibility, most of the MRI contrast agents, such as 
Endorem® or Resovist®, were coated in dextran or dextran derivatives (Laniado and 
Chachuat 1995; Riemer, Hoepken et al. 2004). Therefore unformulated Resovist® 
(Ferucarbotran) and seven commercially available and dextran coated iron oxide 
nanoparticles were chosen with a hydrodynamic diameter between 50-100 nm.  
 
Particles with sizes between 50-70 nm have been shown to have a better half life in 
the blood than similar nanoparticles of a larger size due to their rapid clearance by the 
reticuloendothelial system (RES) (Kalber, Smith et al. 2005; Boyer, Whittaker et al. 
2010; Ruoslahti, Bhatia et al. 2010). The rationale behind this is that a longer half life 
will allow for more particles to accumulate in the tumour due to the enhanced 
permeability and retention (EPR) effect (Greish 2010) and are therefore potentially 
better suited for hyperthermia application. 
 
Even though a smaller hydrodynamic diameter of the magnetic nanoparticles would 
potentially benefit hyperthermia, as especially below the size of 20 nm, as it would 
encourage Néel relaxation. However, an ideal core diameter between 11-15 nm 
(Gonzales-Weimuller, Zeisberger et al. 2009), depending on the magnetic field 
strength and frequency, leaves little space for coating and functionalisation. 
Additionally, since the coating to iron ratio is higher, a substantially higher 
concentration of magnetic nanoparticles would be necessary. 
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2.2 Objectives 
The objectives of the research described in this chapter were to: 
1. Identify suitable commercial nanoparticles 
2. Determine appropriate techniques for the  
a. Study of properties of the nanoparticles 
b. Characterisation of the scFv antibody fragments 
c. Functionalising nanoparticles with scFv antibody fragments  
d. Purification and characterisation of SPION-scFv conjugates 
e. Antibody targeted magnetic nanoparticle hyperthermia in vivo 
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2.3 Materials 
2.3.1 Nanoparticles 
Details of the SPIONs investigated are shown in Table 2.12, as provided by the 
supplier in the specifications. 
 
Table 2.1: Details of SPIONs investigated 
Commercial Name Supplier Coating 
Particle 
Conc. 
[mg/ml] 
fluidMAG-DX 50 nm Chemicell GmbH Dextran 100 
fluidMAG-DX 100 nm Chemicell GmbH Dextran 25 
fluidMAG-CMX 100 nm Chemicell GmbH Carboxymethyldextran 25 
fluidMAG-DXS 100 nm Chemicell GmbH Dextran-sulfate 25 
nanomag-D-spio 100 nm Micromod GmbH Dextran 25 
nanomag-CLD-spio 100 nm Micromod GmbH Cross-linked dextran with NH2 groups 
5 
BNF-starch 100 nm Micromod GmbH Starch 25 
Ferucarbotran Meito-Sangyo Co Ltd Carboxylated dextran N/A* 
[* The manufacturer only provided the atomic iron concentration] 
 
2.3.2 Human Cell Lines 
The human cell lines A375M – melanoma, SW1222 – colorectal carcinoma, and 
LS174T – human colorectal adenocarcinoma, were purchased from ECACC, the 
European Health Protection Agency Culture Collections, while Capan-1 – human 
pancreatic adenocarcinoma, were acquired through ATCC, the American Type 
Culture Collection. 
 
2.3.3 Proteins 
Carcinoembryonic antigen (CEA) was obtained in from Sigma-Aldrich, while NA1 
subunits of CEA were purified as described by Sainz-Pastor et al. (Sainz-Pastor, 
Tolner et al. 2006) 
 
2.3.4 Antibodies 
ScFv variants shMFEm, shNFEm and shMFEm-Cys were produced using the 
methanol inducible Pichia pastoris production platform with secretion of the target 
protein into the media (Tolner, Smith et al. 2006). Briefly, linearized plasmids 
encoding the respective proteins were introduced into Pichia pastoris X33 (Invitrogen) 
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by electroporation and clones were selected on 100 µg/ml zeocin. Out of 5-10 clones 
the best scFv expressing cell-line was chosen and taken forward for fermentation 
(Tolner, Smith et al. 2006). Radial flow bed adsorption IMAC was used as primary 
capture step (Tolner 2013), followed by a cross-flow concentration step. Finally, the 
protein was purified using size exclusion chromatography.  The fraction containing the 
monomer scFv was collected and stored at -80 °C 
 
Mouse tetra his (anti-His) antibody was purchased from Qiagen (Crawley, UK). 
Mouse anti-dextran antibody was bought from StemCell Technologies (Vancouver, 
Canada). Sheep anti-mouse HRP antibody was obtained from Invitrogen (Oregon, 
US). Rabbit cleaved caspase-3 antibody and rabbit HSP70 antibody were purchased 
from Cell Signaling Technology (Massachusetts, US). Goat anti-rabbit HRP antibody 
was kindly provided by Dr. Barbara Pedley (UCL Department of Oncology) 
 
Further materials, as well as buffer recipes, can be found in Appendix I. 
 
 
2.4 Methods 
2.4.1 Nanoparticle Characterization 
2.4.1.1 Hydrodynamic Diameter 
The hydrodynamic diameter was determined by dynamic light scattering using a 
Zetasizer Nano ZS90 (Malvern, Worcestershire, UK).  
 
Nanoparticles taken from a sample stock were diluted with dH2O to a concentration of 
100 µg particles/ml. 750 µl nanoparticle suspension were transferred to a disposable 
semi-micro UV-cuvette (Brand, Wertheim, DE), inserted into the Zetasizer Nano ZS90 
and measured. After three measurements the cuvette was removed from the 
instrument and discarded.  
 
Next nanoparticles from the same original sample were diluted with 5 mM NaCl to a 
concentration of 100 µg particles/ml. 750 µl of the resulting nanoparticle suspension 
were added to a fresh disposable semi-micro UV-cuvette, inserted and measured 
three times. Consequently nanoparticles from the same sample stock were diluted in 
PBS and measured. This procedure was repeated for all eight nanoparticle samples. 
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2.4.1.2 ζ-Potential 
The ζ-potential was determined using a Zetasizer Nano ZS90 (Malvern).  
 
A disposable folded capillary cell (Malvern) was washed with a 10 ml syringe 
containing 70% IMS, followed by two washes with 10 ml dH2O each. Subsequently 
most of the liquid was forced out with nitrogen gas. Next 0.2 mg nanoparticles were 
suspended in 1 ml 5 mM NaCl and added to the folded capillary cell. The cell was 
sealed off with the stoppers provided, inserted into the Zetasizer Nano ZS90 
(Malvern) and measured. After three series of measurements the folded capillary cell 
was removed, emptied and washed with 70% IMS and dH2O, as previously 
described. The capillary cells were re-used for multiple nanoparticle samples until 
deposits on the electrodes started to appear.  
 
2.4.1.3 Atomic Iron Content 
The atomic iron content was determined using inductively coupled plasma atomic 
emission spectroscopy (ICP-AES). 
 
Nanoparticles taken from a sample stock were diluted with ultrapure H2O to a 
concentration of 100 µg particles/ml. The nanoparticle suspensions were further 
diluted with Aristar grade concentrated HCl. The beakers were covered with watch 
glasses and heated for 30 min in a sand bath until any visible particles were 
dissolved. In the meantime six standard solutions containing 0.1-25 mg Fe/l were 
prepared for calibration. After cooling the samples were further diluted 1:10, so that 
the resulting iron concentration was between 1-10 mg/l. The samples were inserted 
into the Thermo iCap 6500 Duo ICP-AES (Thermo Fisher Scientific, Waltham, MA) 
and measured. 
 
2.4.1.4 Core Size 
The core size of the nanoparticles was determined by transmission electron 
microscopy.  
 
Therefore 100 µg/ml particles of two nanoparticle samples were diluted with dH2O in 
1.5 ml microcentrifugation tubes. Carbon coated copper grids were removed from 
their holder by forceps and dipped into the nanoparticle suspensions. The grids were 
then dried at room temperature, still held by forceps.  
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Once dry the two grids were inserted into the sample rod of the JEOL JEM-1200EX II 
Electron Microscope (JEOL, Tokyo, JP). The electron beam focused, magnification 
adjusted and pictures taken. This procedure was repeated for all eight nanoparticle 
samples. 
 
2.4.1.5 Magnetic Properties 
Magnetic properties of the nanoparticles were assessed by SQUID magnetometry 
using the MPMS® SQUID VSM (Quantum Design, San Diego, USA). 
 
Samples were prepared in polycarbonate holders using a small amount of cotton fibre 
(1-2 mm) to absorb 2-4 µl of nanoparticle solution (as received from the 
manufacturer) allowed to dry at RT.  
 
Consequently, the sample holder was assembled, fixed into a brass sample rod and 
mounted onto the carbon rod. Next the lid off the MPMS® SQUID VSM was taken off 
and the carbon rod carefully inserted.  
 
On the computer the magnetic field was set with the set point at 1000.00 Oe, rate 
700.00 Oe/s and approach linear. Next the sample was located, the sample offset 
determined and the measuring sequence started. 
 
2.4.1.6 Heating Potential 
The heating potential was assessed by the magnetic alternating current hyperthermia 
(MACH) system (see Fig. 2.1), which generates an alternating magnetic field of 1.15 
MHz and 13.5 kA/m. [The MACH system was kindly provided by Dr. Paul Southern of 
the Royal Institution of Great Britain.] 
 
The particular frequency chosen for this system represents the practical frequency for 
the theoretical maximum energy loss (Χ”) (see section: 1.3.1.4 and Appendix II). 
Practical, because in order to achieve the theoretical maximum energy loss, particles 
would have to be highly monodisperse, which still remains a challenge. Additionally, 
the goal of the engineers behind the system was to investigate the highest attainable 
frequency using conventional and affordable analogue electronics, which led to  
1.15 MHz. 
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Fig. 2.1 Experimental set-up of the MACH system 
 
In order to determine the heating potential using the MACH system, nanoparticles (1 
mg Fe, according to the ICP-AES results) were transferred into a 1.5 ml 
microcentrifugation tube together with dH2O to a total volume of 1 ml. A hole was 
drilled into the lid of the tube, before it was sealed with parafilm and an optical 
temperature probe (Luxtron, Santa Clara, CA) inserted into the center of the liquid 
sample. Next the sample was placed into the horizontal and vertical center of the 
copper coil of the MACH system.  
 
The voltage on the power supply, over the course of 15 seconds, was increased to 
145 V and 0.92 A to generate an alternating magnetic field of 1.15 MHz and 13.5 
kA/m and the temperature recorded. After 25 min the power input was carefully 
decreased over the course of 15 seconds and the sample let to cool down before the 
procedure was repeated for another two times. 
 
For SAR or ILP measurements, 1 ml was taken from the stock nanoparticle 
suspension (as received from the manufacturer) of each sample and transferred into 
a 1.5 ml microcentrifugation tube. A hole was drilled into the lid of the tube, before it 
was sealed with parafilm and an optical temperature probe (Luxtron) inserted into the 
center of the liquid sample. Next the sample was placed into the horizontal and 
vertical center of the copper coil of the MACH system. The voltage on the power 
supply was increased over the course of 15 seconds and the initial temperature 
Water supply Power supply 
Temperature 
probes 
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increase, during the first two minutes, was recorded. However, when a sample 
reached 65 °C before this, the measurement was stopped, to prevent the probes 
being damaged by the heat. 
 
 
2.4.2 Protein Characterization 
2.4.2.1 Protein Quantification 
The concentration of proteins was determined by spectrophotometry using the 
following equation: 
A280 = ε280 ⋅c ⋅ l  Equation 2.1 
Where A280 is the absorbance at 280 nm of protein samples measured in quartz 
cuvettes on a Cecil CE2041 2000 series spectrophotometer, ε280 is the extinction 
coefficient (0.1%, 280 nm, 1 cm path length) of the protein calculated based on the 
protein primary amino acid sequence using the Expasy Protparam web tool 
(http://www.expasy.ch/tools/protparam.html), c is the protein concentration, l is the 
path length of the cuvette (1 cm). For shMFEm, shMFEm-Cys and shNFEm,  
ε280 = 1.75 
 
2.4.2.2 Sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) 
Gel electrophoresis of proteins was performed under reducing conditions. Samples 
were prepared by the addition of 4X reducing buffer or non-reducing buffer followed 
by denaturation at 95 °C for 4 min. Samples were loaded onto 12% Tris-Glycine pre- 
cast mini-gel (Invitrogen) and separated on an XCell II™ Mini-Cell system (Invitrogen) 
in running buffer on an automated program of 90 min at 35 mA (125 V, 5 W) using a 
PowerEase®  500 power supply (Invitrogen).  
 
Following electrophoresis, proteins were either stained with coomassie blue for two 
hours at room temperature. To enable visualisation of proteins the gels were de-
stained with de-staining solution for another two hours with repeated de-stain solution 
changes. Gels were rinsed carefully with dH2O followed by 15 min incubation in gel 
drying solution (Invitrogen) in preparation for drying using the Invitrogen gel drying kit. 
Two gel drying plastic sheets (Invitrogen) were soaked in the gel drying solution; the 
gel was sandwich between them and left to dry in a drying rack overnight at room 
temperature. 
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2.4.2.3 Enzyme-linked immunosorbent Assay (ELISA) 
ELISA was performed on a 96-well plate (Costa, High Wycombe, UK) coated for  
1 hour with 100 µl 1 µg/ml CEA in PBS or PBS only on the control wells. The wells 
were washed two times with PBS and blocked with 200 µl 5% milk powder (Marvel) in 
PBS for 1 hour at RT. 50-100 µl sample were applied to CEA or PBS coated wells in 
triplicate and incubated for another hour. After incubation the wells were washed 
three times with PBS. The wells were then incubated for 1 hour with 100 µl primary 
antibody diluted in 1% milk powder in PBS. Following incubation wells were washed 
three times with PBS-T (PBS with 0.1% Tween-20) followed by three washes with 
PBS. The plate was then incubated for another hour with 100 µl HRP-conjugated 
secondary antibody diluted in 1% milk powder in PBS. The wells were again washed 
with PBS-T and PBS and 100 µl OPD (O-phenylenediamine dihydrochloride; 0.4 
mg/ml dissolved in phosphate citrate buffer, pH 5.0) was added. Reactions were 
stopped with 50 µl 4 M HCl and the absorbances were measured at 490 nm using 
Opsys MR™ Microplate Reader (Dynex Technologies). 
 
 
2.4.3 SPION Functionalization with Antibody Fragments 
2.4.3.1 Carbodiimide Conjugation 
Conjugation to the available carboxyl groups on carboxylated dextran-coated 
particles, such as FluidMAG-CMX (Chemicell GmbH) or Ferucarbotran (Meito Sanyo) 
was achieved by adaptation and optimization of the carbodiimide chemistry described 
by DeNardo et al. (DeNardo, DeNardo et al. 2005) . 
 
Ferucarbotran nanoparticle suspension (5.6 mg Fe/ml) were mixed with freshly 
prepared EDC/NHS activation buffer and gently mixed for 10 min at RT. The particles 
were then run through a PD-10 column equilibrated with 0.1 M sodium phosphate 
buffer. 25 µg scFv were added and the mix was put on a rotary shaker for 2 hrs at 
RT. Then 100 µl 50 mM glycine solution were added and the particles gently mixed 
for another hour. Together with 0.1 M sodium phosphate buffer the particle 
suspension was brought up to a volume of 5 ml. This suspension was then 
transferred into a Centriprep YM-50 and centrifuged at 3000 rpm for 5 min. 
 
Before the supernatant was withdrawn and the particle concentrate again diluted 
down to a volume of 5 ml. These washes were repeated two times to remove the 
unbound scFv and glycine from the solution. 
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2.4.3.2 Cyanogen Bromide Conjugation 
Conjugation to the available hydroxyl groups on dextran-coated particles, such as 
FluidMAG-DX (Chemicell GmbH) or Ferucarbotran was achieved by adaptation of the 
cyanogen bromide conjugation protocol recommended by Chemicell. 
 
This involved diluting Ferucarbotran (10 mg Fe/ml) with 50 mM sodium borate buffer 
(pH 8.5). The particles were activated by 50 µl CNBr and incubated for 10 min on ice. 
The reaction was stopped running the mix through a PD-10 column equilibrated with 
PBS. 100 µg scFv were added and the mix was put on a rotary shaker for 24 hrs at 
room temperature. On the next day 100 µl of a 25 mM glycine solution were added 
and the mix was incubated for another hour at RT to block the unused active sites on 
the particles. In three overnight washes on the DynalMagnet the unbound scFv and 
glycine were removed. 
 
2.4.3.3 Site-specific Attachment of scFv to Ferucarbotran 
Site-specific attachment was investigated by combining sodium periodate and 
maleimide chemistry  
 
10 mg sodium periodate were dissolved in 800 µl of a 50 mM sodium borate buffer 
(pH 8.5). Ferucarbotran nanoparticle suspension (10 mg Fe) were added and 
incubated on the roto-torque for 25 min at room temperature wrapped in foil, as this 
step is light sensitive. In the meantime a PD-10 column was equilibrated with 50 mM 
sodium borate buffer. To stop the reaction and remove the excess sodium periodate 
the particles were run through the PD-10 and collected in a fresh 2 ml micro 
centrifugation tube. Immediately 10 mg BMPH, the maleimide linker were added and 
carefully suspended in the particle mix.  
The mix was incubated on the roto-torque for two hours, before 20 µl of 5 M sodium 
cyanoborohydride in 1 M NaOH were added. Consequently the suspension was 
incubated o/n on the roto-torque at RT. 
 
On the next day 100 µl of a 0.1 M glycine in 50 mM sodium borate buffer (pH 8.5) 
solution were added and the mix incubated for another hour on the roto-torque. In the 
meantime a PD-10 column was equilibrated with 50 mM sodium borate buffer (pH 7). 
 
The mix was run through the PD-10 column and collected in a 7 ml sterilin tube 
containing 100 µg shMFEm-Cys. This was gently mixed and put on the roto-torque 
o/n. 
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Subsequently 100 µl of a 0.1 M cysteine in 50 mM sodium borate buffer (pH 8.5) 
solution were added and the mix incubated for another hour on the roto-torque, 
before it was stored for purification and analysis at 4 °C. 
 
 
2.4.4 FX-scFv Conjugate Purification and Characterization 
2.4.4.1 Size Exclusion Chromatography with FX-scFv Conjugates 
In order to purify FX-scFV conjugates size exclusion chromatography was performed. 
Therefore a XK 16/100 column was packed with Sephadex™ G-100 (GE Healthcare), 
expanded in PBS for 72 hrs at RT. The column was mounted on a lab stand and the 
bottom connected to a syringe filled with 70% IMS. Carefully the IMS was pushed up 
resulting in a 1 cm level of IMS inside the column. The syringe was removed and the 
end capped. Next a packing reservoir was mounted on top the column and the 
Sephadex™ G-100 sludge carefully poured into the column avoiding the generation 
of bubbles. The reservoir was filled completely by adding some PBS, before the lid 
was screwed on and the column connected to the ÄKTA prime plus FPLC system 
(Amersham Biosciences). Then sterile filtered PBS was pumped through the column 
at 2 ml/min and not exceeding a pressure of 0.9 mbar. Consequently the flow was 
stopped, the column disconnected and the bottom capped, before the reservoir was 
carefully screwed off and the top (incl. a flow adapter) attached. The flow adapter 
similar to the bottom previously was connected to a syringe containing 70% IMS in 
order to prevent bubble formation. Once the top was screwed on the syringe was 
removed and the flow adapter carefully lowered onto the Sephadex™ G-100.  
 
The column was then connected again to the ÄKTA prime plus and run at 1.5 ml/min 
with a pressure limit of 0.9 mbar over night. On the next day a gel filtration protein 
standard was prepared, injected and run at 0.5 ml/min to establish an elution profile.  
 
To purify FX-scFv conjugates, the conjugation mix (1-2 ml) was applied to the column 
and run at 0.5 ml/min, as shown in Fig. 2.2. The fractions coming out with the void 
were collected and consequently concentrated using a Centriprep YM-50 (Millipore) 
and multiple centrifugation runs, depending on the total volume, at 4000 rpm for 10 
min. 
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Fig. 2.2 Experimental set-up for the purification of the FX-scFv conjugates consisting of an 
ÄKTA prime plus FPLC system and XK 16/100 column was packed with Sephadex™ G-100.  
 
 
2.4.4.2 Enzyme-linked immunosorbent assay (ELISA) with FX-scFv Conjugates 
ELISA with FX-scFv conjugates was performed on 96-well MaxiSorp™ plates (Nunc). 
Therefore the plate was divided in two halves and each coated in triplicates with  
100 µg/ml FX, FX-shMFEm, FX-shNFEm; 100 µg/ml shMFEm, shNFEm; and PBS 
and incubated for 1 hour at RT. The wells were washed two times with PBS and 
blocked with 200 µl 5% milk powder (Marvel) in PBS for 1 hour at RT. After incubation 
the wells were washed three times with PBS. The wells of the one half of the plate 
were then incubated for 1 hour with 100 µl anti-His antibody (1:500) diluted in 1% milk 
powder in PBS, while the wells on the other half were incubated for 1 hour with 100 µl 
anti-dextran antibody (1:1000). Following incubation wells were washed three times 
with PBS-T (PBS with 0.1% Tween-20) followed by three washes with PBS. 
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The plate was then incubated for another hour with 100 µl HRP-conjugated 
secondary antibody diluted in 1% milk powder in PBS (1:1000). The wells were again 
washed with PBS-T and PBS and 100 µl OPD (O-phenylenediamine dihydrochloride; 
0.4 mg/ml dissolved in phosphate citrate buffer, pH 5.0) was added. Reactions were 
stopped with 50 µl 4 M HCl and the absorbances were measured at 490 nm using 
Opsys MR™ Microplate Reader (Dynex Technologies). 
 
2.4.4.3 ECL Western Blotting with FX-scFv Conjugates 
In order to perform an enhanced chemiluminescence (ECL) western blot with FX-
scFv conjugates first native gels were cast using a hand casting gel kit (Bio-Rad 
Laboratories Ltd.).  
 
A 2% agarose in dH2O solution was prepared and heated up in a microwave. About 
15 ml hot agarose solution were poured onto the cleaned bench top, before the kit 
was carefully placed in it and the agar left to gel and cool. In the meantime in order to 
prepare a 12% resolving gel 3.25 ml dH2O, 5.6 ml 1 M Tris pH 8.8, 150 µl 10% SDS, 
6 ml Acrylamide stock and 50 µl 10% APS were added to tube and mixed. Then 10 µl 
TEMED were mixed in the solution carefully poured into the immobilized kit. Quickly a 
couple of ml 100% IMS were added to the kit. After a couple minutes a sharp edge 
between gel and IMS developed. The kit was carefully removed from the agar on the 
bench top, the IMS emptied out. Next 3.65 ml dH2O, 625 µl 1 M Tris pH 6.8, 50 µl 
10% SDS, 820 µl acrylamide stock and 25 µl 10% APS were mixed for a 4% stacking 
gel. 5 µl TEMED were mixed into the solution before it was carefully poured on top of 
the resolution gel in the kit. Quickly the comb for the wells was inserted.  
 
After gelation the glass plates with gel were transferred into the gel electrophoresis 
chamber. The comb removed and the chamber filled with running buffer. FX-scFv 
conjugates and controls were mixed with 4X non-reducing buffer, loaded onto the 
hand cast gel and run for 90 min at 35 mA (125 V, 5 W).  
 
Then proteins were transferred to polyvinylidene difluoride (PVDF) membrane (Bio-
Rad Laboratories Ltd.), pre-treated by soaking in methanol for 10 min. Gels were 
sandwiched with the PVDF membrane between several sheets of pre-wetted 
chromatography filter paper (Whatmen, Maidstone, UK) and sponges. The “sandwich” 
was then submerged in an XCell II Blot Module (Invitrogen) filled with transfer buffer. 
Proteins were transferred using an automated program of 90 min at 125 mA  
(25 V, 17 W). 
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Following electro-transfer, PVDF membranes were blocked in 5% milk powder in PBS 
for one hour. Next the membranes were washed in PBS and incubated on a rocker at 
room temperature for another hour subjected to an anti-His antibody (1:500) diluted in  
1% milk powder in PBS. Consequently the membranes were washed with three times 
with PBS-T (0.1% Tween-20 in PBS) and three times with PBS only. Next they were 
incubated again on the rocker for another hour in 1% milk powder in PBS containing a 
horseradish peroxidase (HRP) conjugated secondary antibody (1:1000).  
 
Finally, the membranes were washed again with PBS-T and PBS and treated with 
ECL Plus Western Blotting Detection Reagents (GE Healthcare) to allow the proteins 
to visualize. The Western Blots were put into plastic wrap and imaged for 30 s using a 
Kodak imaging cassette (Kodak) and Kodak Bio-Max MR-1 film (Kodak) in the dark 
room followed by developing the film in the developer.  
 
2.4.4.4 Quartz Crystal Microbalance 
Quartz crystal microbalance (QCM) was performed by immobilizing the scFvs or  
FX-scFv conjugates on sensor chip and treating them with different concentrations of 
the antigen NA1 using the Attana A200® Biosensor (Attana, Sweden). 
 
For immobilization and analysis of the scFvs the carboxyl sensor chips were inserted 
into channel A and B of the Attana A200 and equilibrated by running sterile filtered 
PBS over them at 20 µl /min until the baseline stabilized. Next 50 µl EDC/NHS were 
injected to both channels followed by shMFEm in channel A and shNFEm in channel 
B. The chips were then blocked with 35 µl BSA each. In between each step buffer 
was run over the sensor chips at 10 µl /min.  
 
For the measurements 35 µl of concentration 1 of the antigen NA1 (5 ng/ml) were 
injected on both channels followed by PBS at 10 µl/min for 10 min. The sensor chips 
were regenerated pulsing them for 15 sec with 100 mM glycine pH 3, before they 
were equilibrated again with PBS. This procedure was repeated for all concentrations 
of antigen ranging from 5 – 50 ng/ml. 
 
The FX-scFv conjugates were immobilized by manually injecting two PS sensor chips 
with 1 mg particles/ml FX-shMFEm and FX-shNFEm and incubating them overnight 
at 4 °C. Then the sensor chips were inserted into Channel A and B of the Attana 
A200 and equilibrated with PBS at 20 µl/min until the baseline stabilized. Next the 
sensor chips were blocked with 35 µl BSA each and followed by PBS. 
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2.4.5 Cell Culture 
2.4.5.1 Thawing Cell Stock from Cryostorage 
In order to start a fresh cell line a laminar class II cabinet was started and disinfected. 
Next the appropriate media (see Table 2.9) was prepared and warmed up to 37 °C in 
a water bath. 18 ml medium were transferred into a T-75 cell culture flask left for one 
hour in the incubator at 37 °C and 5% CO2 to equilibrate.  
 
A frozen stock vial was removed from the liquid nitrogen tank and quickly thawn in the 
waterbath. The cells were resuspended, transferred into the cell culture flask and 
incubated o/n. On the next day the cells were checked under the microscope and the 
medium was replaced.  
 
2.4.5.2 Sub-culturing Cell Lines 
Once about 70% confluency was reached, cells were sub-cultured twice a week in a 
specific split ratio depending on their growth. This was achieved through withdrawal 
of the medium, two gentle washes with 5 ml PBS, release of the cells by addition of. 
The trypsin-EDTA was then neutralized by the addition of 12 ml PBS, the cell 
suspension spun down at 1500 rpm for 3 min, the supernatant discarded and the cell 
pellet resuspended in 10 ml medium. 2 ml cell suspension were transferred into a 
new cell culture flask together with 18 ml fresh medium and put back into the 
incubator. 
 
2.4.5.3 Preparing Cell Lines for Cryostorage 
In order to preserve cells, a freezing medium with 5% DMSO was prepared. Then the 
cells were treated as for sub-culturing. The media was withdrawn, followed by two 
gentle washes with 5 ml PBS and release of the cells by the addition of 3 ml trypsin-
EDTA and incubation for 3-6 min at 37 °C. The trypsin-EDTA was then neutralized by 
the addition of 12 ml PBS, the cell suspension spun down at 1500 rpm for 3 min, the 
supernatant discarded and the cell pellet resuspended in 1 ml medium. 20 µl were 
transferred to a previously cleaned hemocytometer or counting chamber. The cells 
were then counted. Next the cells were diluted with freezing media to a final 
concentration 1 x 106 cells/ml. The cell suspension was then quickly transferred into 
1.8 ml cryovials (Nunc) and frozen at -80 °C. After 1-2 hours the cells were 
transferred into liquid nitrogen until further use. 
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2.4.5.4 Immunostaining Adherent Cells 
In order to fluorescently label cells, cells were seeded on 13 mm round glass 
coverslips (VWR) in a 24-well plate (Corning) at a density of 1 x 105 cells/well 
together with 500 µl media. Once the cells reached the desired confluency the media 
was carefully aspirated, the wells washed with PBS and the cells fixed with 4% 
paraformaldehyde for 20 min. This was followed by three washes with PBS and 
incubation with 50 mM glycine for 10 min. Next the wells were washed again three 
times with PBS and blocked with 3% BSA in PBS for one hour. The slides were 
washed again with PBS, before they were removed from the wells using tweezers 
and set on the upside down turned cut off caps of microcentrifugation tubes in a small 
chamber humidified by Kim wipes wetted with PBS. Quickly 100 µl of 1% BSA in PBS 
solution with a mouse anti-CEA antibody were added to each slide and incubated for 
one hour at RT. The slides were washed with PBS. Another 100 µl of 1% BSA in PBS 
solution with an Alexa Fluor labeled anti-mouse antibody were added to each slide. 
The slides were then incubated in the dark at RT for another hour. Next the slides 
were washed with PBS three times and treated with a drop DAPI mounting solution in 
1 ml PBS for 30 sec. The slides were quickly washed again in PBS and mounted on 
glass slides with a drop of ProLong® Gold Antifade (Invitrogen). The slides were 
sealed off with transparent nail varnish and immediately imaged using the fluorescent 
microscope (Leica). 
 
 
2.4.6 Magnetic Nanoparticle Hyperthermia in vivo 
All animal work was carried out according to the Home Office License with the help of 
Mathew Robson and Mario Mazzantini (Department of Oncology) at the Wolfson 
Institute of Biomedical Research. 
 
2.4.6.1 Inducing and Establishing Xenografts 
In this thesis different xenograft models were investigated. The CEA positive human 
cell lines SW1222, LS174T and Capan-1 were used to induce tumours in the left flank 
of female MF1 nude mice (Charles River Laboratories International Inc). The mice 
were 2-3 months old, weighing 20-25 g, when 1 x 106 cells in saline were injected 
subcutaneously. Within 2-3 weeks the tumour volume increased to 0.75 – 1.1 cm3. 
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2.4.6.2 Non-Targeted Magnetic Nanoparticle Hyperthermia 
For this experiment seven mice carrying SW1222 xenografts were grown and split 
into two treatment groups and one negative control. One group of three was treated 
with fM-DX 100, while the other group received Ferucarbotran. In each group one 
mouse received a high dose (2 mg Fe per tumour) without being subjected to the 
alternating magnetic field, while the remaining mice received a high dose or low dose 
(0.5 mg Fe per tumour) together with AMF.  
 
Therefore, one mouse at a time was anesthetized with isofluorane, injected with the 
adequate amount of particle and immediately transferred to the copper coil of MACH 
system. The alternating magnetic field was switched on and the voltage on the power 
supply increased over the course of 15 seconds to a maximum of 145 V and 0.92 A. 
The mouse was treated for 20 min. The temperature development on the surface of 
the mouse was monitored via thermal imaging. The experimental set-up can be found 
in Fig. 2.1. Additionally, an optical temperature probe was inserted into the anus of 
the two mice treated with Ferucarbotran (and subjected to the AMF) to record internal 
temperature. 
 
Afterwards, the mouse was allowed to recover in an oxygenated environment, before 
it was put back into the cage. 40 min later the mouse was sacrificed, the tumour 
excised and put into 4% formalin for further processing (preservation in paraffin) and 
analysis. This procedure was repeated for every mouse according to the above 
mentioned treatment regimen. 
 
2.4.6.3 Identifying Suitable Tumour Model for Magnetic Nanoparticle Hyperthermia 
For this experiment a total of six mice were induced with SW1222, LS174T and  
Capan-1 xenografts - two mice per tumour type.  
 
One mouse at the time was anesthetized with isofluorane and injected iT with 
Ferucarbotran (3 mg Fe/cm3 tumour volume) as described by Giustini et al. The 
needle remained in place for 5 minutes post-injection. (Giustini, Ivkov et al. 2011) 
Afterwards the mouse was left to recover for 25 min and sacrificed. The tumour was 
excised, processed and put into paraffin for further analysis. This procedure was 
repeated with each tumour. 
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2.4.6.4 Antibody-Targeted Magnetic Nanoparticle Hyperthermia 
For this experiment seven mice carrying LS174T xenografts were grown and split into 
two treatment groups and one negative control. One group of three was treated with 
Ferucarbotran functionalized with shMFEm (FX-shMFEm), while the other group 
received FX-shNFEm. The negative control was injected with PBS only. 
 
One mouse at the time was anesthetized with isofluorane and injected iT with either 
FX-shMFEm or FX-shNFEm (3 mg Fe/cm3 tumour volume). The needle remained in 
place for 5 minutes post-injection. The mouse was then either left to recover in the 
cage for 55 min before it was sacrifized (two control mice per group), or subjected to 
an alternating magnetic field (AMF) for 25 min, as shown in Fig. 2.1. The surface 
temperature of the mouse was monitored through thermal imaging.  
 
After the hyperthermia treatment the mouse was left to recover for 30 min and 
sacrifized. The tumour was excised, fixed, processed and put into paraffin for further 
analysis. This procedure was repeated with each tumour. 
 
 
2.4.7 Histology 
2.4.7.1 Prussian Blue Staining 
To verify the location of iron oxide nanoparticles within the tumour tissue sections 
were stained with Prussian blue. Therefore the tissue slides were deparaffinised in 
histoclear for 9 min (3 x 3 min); dehydrated in IMS (100% x 2, then 70% x 1 for 3 min 
each) and washed with distilled water. Next 25 ml of 2% potassium ferrocyanide were 
mixed with 25 ml 2% HCl in a coplin jar. The slides were placed in the jar for 30 min, 
before they were counterstained for 5 min in 0.1% Nuclear Fast Red.  
Afterwards the slides were washed again with distilled water (3 x 3 min), dehydrated 
in IMS (70% x 1, then 100% x 2 for 3 min each) and histoclear (3 x 3 min). The slides 
where subsequently mounted using DPX and imaged with the NanoZoomer Digital 
Pathology System (Hamamatsu, Japan) 
 
2.4.7.2 Cleaved Caspase-3 Staining 
To determine, if nanoparticles induced apoptosis the tissue sections were stained 
with a cleaved caspase-3 antibody. Hence the tissue slides were deparaffinised in 
histoclear for 9 min (3 x 3 min); dehydrated in IMS (100% x 2, then 70% x 1 for 3 min 
each) and washed with distilled water. 
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Next the slides were cooked in the microwave for 10 min in 0.01 M citrate buffer (pH 
6). The slides were then thoroughly washed with tap water and PBS/T. The tissue 
was marked with a wax pen and the endogenous peroxidase blocked with 3 % 
hydrogen peroxide in methanol for 10 min. This was followed by 3 x 3 min washes 
with PBS/T. 3 % goat serum diluted in PBS/T was applied for 20 min at RT, then the 
primary antibody, Cleaved casp.-3 (Asp 175) (5A1) (Cell Signaling Technology), 
diluted 1/100 in PBS/T, was applied and the slides incubated at 4 °C o/n. 
 
On the next day the slides were thoroughly washed with PBS/T (3 x 3 min) before the 
secondary antibody, polyclonal goat anti rabbit IgG biotinylated Ab (Abcam), diluted 
1/200 in PBS/T, was applied for 30 min at RT. At the same time the AB complex was 
prepared by adding one drop of reagent A and one drop of reagent B to 2.5 ml 
PBS/T. The slides where thoroughly washed with PBS/T (3 x 3 min) and incubated 
with AB complex for 30 min at RT. This was followed by another series of washes (3 x 
3 min with PBS/T). Next DAB (1/50) was applied for up to 10 min or when the colour 
was sufficient. Then the slides where thoroughly washed with tap water, 
counterstained with haematoxylin and thoroughly rinsed with tap water. Afterwards 
the slides were dehydrated in IMS (70% x 1, then 100% x 2 for 3 min each) and 
histoclear (3 x 3 min). Subsequently the slides were mounted with DPX and imaged. 
 
2.4.7.3 Heat Shock Protein 70 (HSP70) Staining 
To determine, if nanoparticles were inducing heat stress, the tissue sections were 
stained with a HSP70 antibody. Therefore the tissue slides were deparaffinised in 
histoclear for 9 min (3 x 3 min); dehydrated in IMS (100% x 2, then 70% x 1 for 3 min 
each) and washed with distilled water. Next the slides were cooked in the microwave 
for 10 min in 0.01 M citrate buffer (pH 6). The slides were then thoroughly washed 
with tap water and PBS/T. The tissue was marked with a wax pen and the 
endogenous peroxidase blocked with 3 % hydrogen peroxide in methanol for 10 min. 
This was followed by 3 x 3 min washes with PBS/T. 3 % normal rabbit serum diluted 
in PBS/T was applied for 20 min at RT, then the primary antibody, HSP70 (6B3) rat 
mAb (Cell Signaling Technology), diluted 1/200 in PBS/T, was applied and the slides 
incubated for 1 hour at RT. 
 
After incubation the slides were thoroughly washed with PBS/T (3 x 3 min) before the 
secondary antibody, polyclonal rabbit anti rat IgG biotinylated Ab (Abcam), diluted 
1/200 in PBS/T, was applied for 30 min at RT. At the same time the AB complex was 
prepared by adding one drop of reagent A and one drop of reagent B to 2.5 ml 
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PBS/T. The slides where thoroughly washed with PBS/T (3 x 3 min) and incubated 
with AB complex for 30 min at RT. This was followed by another series of washes  
(3 x 3 min with PBS/T). Next DAB (1/50) was applied for up to 10 min or when the 
colour was sufficient. Then the slides where thoroughly washed with tap water, 
counterstained with haemotoxylin and thoroughly rinsed with tap water. Afterwards 
the slides were dehydrated in IMS (70% x 1, then 100% x 2 for 3 min each) and 
histoclear (3 x 3 min). Subsequently the slides were mounted with DPX and imaged. 
 
 
2.5 Summary 
The aim of this chapter was to select appropriate techniques for the characterisation 
of the nanoparticles, as well as the scFv antibody fragments, the functionalisation of 
the nanoparticles with the scFv antibody fragments, the purification and 
characterisation of the SPION-scFv conjugates and the antibody targeted magnetic 
nanoparticle hyperthermia in vivo. 
 
These particular techniques were selected based on recommendations, as well as 
specific literature and the resources available. 
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Chapter 3 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3 A Study of Properties of Magnetic 
Nanoparticles for Hyperthermia 
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3.1 Introduction 
The work described in this chapter shows the characterization and evaluation of the 
heating potential of different MNP to identify the most suitable candidate for 
hyperthermia application. 
 
The most apparent difference between MNP is their hydrodynamic diameter, however 
also a number of other physical factors have been demonstrated to influence the 
heating potential of MNP (Pankhurst, Connolly et al. 2003; Krishnan 2010). In order to 
maximize their hyperthermic potential, the iron oxide should be between 11-15 nm 
depending on the field conditions (Gonzales-Weimuller, Zeisberger et al. 2009; 
Kallumadil, Tada et al. 2009; Krishnan 2010) to encourage Néel relaxation rather than 
Brownian motion as the main heating mechanism (see section: 1.3.1).  
 
Another way to improve the heating potential of magnetic nanoparticles is to change 
the core material from iron oxide to a magnetically more favourable material, such as 
cobalt ferrite or manganese ferrite. Currently the best heating magnetic nanoparticles 
are CoFe2O4@MnFe2O4 core shell nanoparticles with a SAR of up to 4000 W/g at  
500 kHz and 37.3 kA/m (Lee, Jang et al. 2011). However, the toxicity of these 
particles is barely understood.  
 
Iron oxide is deemed safe, as the particles administered for imaging represent only a 
small fraction (1.25 – 5%) of the total human iron stores (Tsourkas 2009). Still, 
especially in cases of regional deposition of iron oxide nanoparticle for biomedical 
applications, such as hyperthermia, there remains a potential risk of local toxicity 
(Singh, Jenkins 2010). 
 
Since MNP differ with regard to the coating to iron ratio, core composition and size, 
the atomic iron content was chosen as the common denominator to compare heating 
potentials. 
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3.2 Objectives 
The objectives of the research described in this chapter were to: 
1. Determine hydrodynamic diameter and size distribution of the MNP 
2. Measure zeta potential of the MNP 
3. Determine structure and core size of the MNP 
4. Quantify the atomic iron content 
5. Determine magnetic properties of the MNP 
6. Determine heating potential of MNP using the MACH system. 
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3.3 Results 
3.3.1 Hydrodynamic Diameter and ζ-Potential 
The first parameter to be assessed was the hydrodynamic diameter, as it provides not 
only information about the overall size of the nanoparticles, but also the distribution of 
sizes in a suspension. The hydrodynamic diameter was determined by dynamic light 
scattering (DLS) using a Nanosizer ZS90 (Malvern). Therefore, 10 µg particles were 
suspended and measured at least three times in 1 ml dH2O, 5 mM NaCl and PBS. 
These buffers were chosen, as different salt concentration is known to affect the 
hydrodynamic diameter of nanoparticles with certain coatings, like dextran. 
 
[Note: Due to a limitation in the software of the Nanosizer ZS90, the raw data could 
not be exported; instead screenshots were taken and recorded.] 
 
 
Fig. 3.1 Hydrodynamic size distributions (by intensity) of Ferucarbotran in distilled water (red 
line), 5 mM NaCl (green line) and PBS (blue line) showing an average size of 55.55 nm (z-
average) with a Pdl of 0.184, indicating polydispersity and an average intensity peak at  
69.22 nm. The result quality ‘good’ indicates that the sample matched the requirements of the 
system for a successful measurement. Each line represents a single measurement. 
[Screenshot taken from DTS Nano program] 
 
The Nanosizer ZS90 and its corresponding software, DTS Nano (Malvern), provided 
different values for interpreting the size (Fig. 3.1), such as the z-average. This 
particular value is an average taken from across the size distribution, while the peak 
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value represents the most prevalent size within the nanoparticle suspension. 
Therefore, the peak values were used to assess particle sizes as presented in Table 
3.1 and Fig. 3.2. The polydispersity index (PdI) the width of the size distribution and 
suspensions with a PdI bigger than 0.100 are considered polydisperse. Since the size 
affects the heating mechanisms, a narrow size distribution with a low Pdl is 
favourable (Hergt, Dutz et al. 2008). If the size distribution is too wide, only a small 
part of the particle suspension will contribute to the heating potential (see section: 
1.3.1). 
 
Table 3.1 Determined hydrodynamic diameters of nanoparticles in dH2O, 5 mM NaCl and PBS 
Sample dH2O 5 mM NaCl PBS 
fM-DX 50 49 50 50 
fM-DX 100 197 183 184 
fM-CMX 100 106 N/A N/A 
fM-DXS 100 79 N/A N/A 
nm-D-spio 100 88 87 89 
nm-CLD-spio 100 147 111 102 
BNF-starch 100 136 136 134 
Ferucarbotran 77 68 69 
 
As all samples were supplied suspended in dH2O, quite surprisingly, some 
nanoparticles were substantially bigger than the manufacturers specifications. The 
biggest discrepancy between specification and determined hydrodynamic diameter 
was observed in the fM-DX 100 samples, as the data showed a size of 183-197 nm 
instead of 100 nm. Also BNF-starch 100 and nm-CLD-spio 100 were found to be 
considerably bigger than their name and specifications indicated. However, the 
values obtained from the nm-CLD-spio 100 in 5 mM NaCl and PBS were within an 
acceptable range of 102-111 nm.  
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Fig. 3.2 Determined hydrodynamic diameters of commercial nanoparticles suspended in 
distilled water (blue), 5 mM NaCl (red) and PBS (green). The number next to the nanoparticle 
name represents the size specifications provided by the manufacturer. fM-CMX 100 and fM-
DXS were not stable in 5 mM NaCl and PBS and precipitated, therefore no values could be 
obtained. fM-DX 100 with 183-197 nm demonstrated almost twice the size suggested by the 
specifications. Overall minor differences of particles between buffers were observed, except 
for fM-CLD, showing 30% bigger size in dH2O compared to 5 mM NaCl and PBS. Detailed 
numbers for each particle and buffer can be found in Table 3.1. 
 
 
fM-CMX 100 and fM-DXS 100 were measured only in water, as they started to 
precipitate immediately after suspension in 5 mM NaCl and PBS and their 
hydrodynamic diameter increased as shown in Fig. 3.2. The reason for this is that 
both, fM-CMX 100 and fM-DXS 100, had highly charged functional groups within their 
coating, such as carboxyl (fM-CMX) and sulphate (fM-DXS) groups, allowing sodium 
(Na+) and chloride (Cl-) ions to form solid salts. 
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Fig. 3.3 Determined hydrodynamic size distributions of fM-CMX in dH2O (red line) and 5 mM 
NaCl (green line). fM-CMX in dH2O shows a normal distribution with a peak at 100 nm, fM-
CMX suspended 5 mM NaCl shows a lower peak at around 150 nm and higher peak at 
around 600 nm, with an overall distribution ranging from 60 – 2000 nm revealing particle 
aggregation and precipitation. Each line represents a single measurement. [Screenshot taken 
from DTS Nano program]  
 
 
Fig. 3.4 Hydrodynamic size distributions of nm-CLD-spio in dH2O (red line), 5 mM NaCl (green 
line) and PBS (blue line) showing a shift of the different distributions and thus a deviation in 
peak values (see Table 3.1). Each line represents a single measurement. [Screenshot taken 
from DTS Nano program] 
 
Even though the different buffers did not affect most particles, in the case of the 
cross-linked dextran nanoparticles, nm-CLD-spio 100, their size decreased in the 
presence of ions by 25-30% in 5 mM NaCl and PBS (Fig. 3.3 and Table 3.1) as the 
shift in distribution suggests. However, size distribution did not widen, indicating that 
this was not caused through agglomeration of the particles. 
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The Nanosizer ZS90 (Malvern) also provided the option to determine the ζ-potential, 
which is important information on how the particles will interact with cells. Highly 
positively or negatively charged particles are taken up more rapidly than neutral 
particles (Mailander and Landfester 2009).  The ζ-potential is the electric potential of 
a double layer of ions around the nanoparticles and therefore measured in the 
presence of 5 mM NaCl. 
 
Table 3.2 Measured ζ-potential for different nanoparticles 
Sample ζ-potential [mV] 
fM-DX 50 -1 
fM-DX 100 -1 
fM-CMX 100 N/A* 
fM-DXS 100 N/A* 
nm-D-spio 100 -5.5 
nm-CLD-spio 100 -4 
BNF-starch 100 0 
Ferucarbotran -23 
[* No values were obtained for fM-CMX 100 and fM-DXS 100, as they were not stable in 5 mM 
NaCl] 
 
As fM-CMX 100 and fM-DXS 100 were not stable in 5 mM NaCl the ζ-potential could 
not be determined. The ζ-potentials of most particles were almost neutral, as dextran 
and starch is not charged, except for Ferucarbotran with a ζ-potential of -23 mV 
coated in carboxylated dextran. This indicates that Ferucarbotran has carboxyl 
groups on the surface, which is important information for possible functionalization.  
 
3.3.2 Atomic Iron Content 
There are various methods of determining the iron content in nanoparticles, but as the 
cores are mostly a mixture of magnetite (Fe3O4) and maghemite (γ-Fe2O3) or other 
iron species, this becomes increasingly difficult, as most methods determine one kind 
of Fe ion. The ferrozine assay, for example, only quantifies Fe2+ ions (Riemer, 
Hoepken et al. 2004), while another assay, a modified version of the Prussian blue 
reaction, as recommended by one manufacturer [Correspondence with CEO Christian 
Bergemann, Chemicell, Germany] only quantifies Fe3+. So, even a combination of 
these assays provides at best a ratio of Fe2+ to Fe3+.  
 
Another method is inductively coupled plasma atomic emission spectroscopy (ICP-
AES), allowing quantification of all iron present independent of their charge. 
Therefore, this method was chosen and, with the kind help and expertise of Stanislav 
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Strekopytov from the Natural History Museum, the atomic iron content of the 
nanoparticles was determined.  
 
Table 3.3 Atomic Fe content determined by ICP-AES compared to the estimated Fe content 
specified by the manufacturers∗1 
 
Sample Particle conc. [mg/ml] 
Estimated Fe 
content [%] Fe [mg/ml] 
Determined 
Fe content 
[%] 
fM-DX 50 100 30-35 30.59 30.59 
fM-DX 100 25 60-70 15.7 62.80 
fM-CMX 100 25 60-70 17.75 71.00 
fM-DXS 100 25 60-70 17.69 70.76 
nm-D-spio 100 25 10 2.39 9.56 
nm-CLD-spio 100 5 50 2.14 42.80 
BNF-starch 100 25 60 14.83 59.32 
Ferucarbotran 55 100 50.69 92.16 
 
[Note: The results in this table represent single measurements, since the time on the 
instrument was limited.] 
 
Overall the iron content of the tested nanoparticles corresponded to the estimated 
values stated in the manufacturer’s specifications1. The iron content of the fM-DX 50 
was significantly lower than in the fM-DX 100, which is not surprising since smaller 
cores require a higher amount of coating. The low iron content of nm-d-spio 100 is 
also a consequence of the coating. These particles have a comparably thicker shell 
than fM-DX 100, fM-CMX 100 or fM-DXS 100 improving their colloidal stability.  
 
In contrast to Micromod and Chemicell, Meito-Sanyo, the manufacturer of 
Ferucarbotran, did not provide a particle concentration, but instead the atomic iron 
concentration; therefore the estimated iron content in Table 3.3 is stated as 100%.  
 
                                                
 
1 For Micromod: Corresponding technical data sheets were found at http://www.micromod.de accessed 12.01.12 
   For Chemicell: Personal correspondence with CEO Christian Bergemann 
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3.3.3 Core Size and Structure 
Other important information to gain an insight into the hyperthermia potential of a 
magnetic nanoparticle is the core size and structure, as this will affect heating 
mechanism (see section: 1.3.1.1). Core size and structure of the nanoparticles was 
determined by transmission electron microscopy (TEM) using the JEOL  
JEM-1200EX II Electron Microscope (JEOL, Tokyo, JP). Therefore 100 µg/ml 
nanoparticles from the stock solution were diluted with dH2O in 1.5 ml 
microcentrifugation tubes. Carbon coated copper grids were removed from their 
holder by forceps and dipped into the nanoparticle suspensions. The grids were then 
dried at room temperature, still held by forceps and consequently viewed and 
analysed under the TEM. Images obtained through TEM mainly show the particles’ 
cores, as they have a much higher electron density than the polymer (Ortega 2012). 
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Fig. 3.5 TEM images of different nanoparticles captured on carbon coated copper grids. (A) 
fM-DX 50 showed core sizes ranging 2-5 nm; (B) fM-DX 100, (C) fM-CMX 100, (D) fM-DXS 
demonstrated similar cores with diameters between from 5-10 nm; (E) nm-d-spio 100 cores 
ranged 4-7 nm, (F) nm-CLD-spio 100 resembled small clusters with sizes between 10-20 nm 
consisting each of several 3-5 nm crystals.  
B A 
D C 
E F 
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While the Chemicell nanoparticles (fM-DX 50, fM-DX 100, fM-CMX 100 and fM-DXS 
100) showed very similar cores (Fig.3.5), the Micromod particles varied in core size, 
but also in shape. nm-d-spio 100 with their round crystals resembled the Chemicell 
particles, nm-CLD-spio 100 resembled more mini-clusters [see (F) in Fig. 3.5]. 
 
 
Fig. 3.6 TEM image of BNF-starch 100 presenting cubelike structure with a core size 
distribution between 5-50 nm, suggesting thermal blockage at room temperature. 
 
Interestingly, the BNF-starch 100 (Fig. 3.6), specifically designed for hyperthermia 
application (Bordelon, Cornejo et al. 2011), showed a completely different core shape 
to the other nanoparticles presenting a cuboid in structure. 
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Fig. 3.7 TEM image of clustered Ferucarbotran cores 4-5 nm in size.  
 
Ferucarbotran consisted mostly of 4-5 nm crystals (Fig. 3.7), similar to the fM-DX 50 
(see A in Fig. 3.5), which is consistent with the literature (Reimer and Balzer 2003). 
 
 
3.3.4 Hysteresis and Magnetic Properties 
Next the magnetic properties of the nanoparticles were assessed by SQUID 
magnetometry using the MPMS® SQUID VSM (Quantum Design, San Diego, US). 
Therefore, five cotton fibers were put into a sample holder and 2-4 µl nanoparticle 
stock solution were added. The sample was let to dry for a couple of hours at room 
temperature before it was analysed in a single run using the SQUID. 
 
The resulting MH curves, magnetisation M vs applied field H, (Fig 3.8-11) indicate 
superparamagnetic behaviour within Ferucarbotran particles and a mix of 
ferromagnetic and superparamagnetic behaviour within fM-CMX 100.  
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Fig. 3.8 Determined MH curves for fM-CMX 100. This MH curve represents a single 
measurement. 
 
 
Fig. 3.9 Determined MH curves for nm-d-spio 100. This MH curve represents a single 
measurement. 
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Fig. 3.10 Determined MH curves for BNF-starch 100. This MH curve represents a single 
measurement. 
 
 
 
Fig. 3.11 Determined hysteresis loop for Ferucarbotran. This MH curve represents a single 
measurement. 
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3.3.5 Heating Potential 
The heating potential of the nanoparticles was determined by using the Magnetic 
Alternating Current Hyperthermia (MACH) system, kindly provided by Dr. Paul 
Southern from the Royal Institution of Great Britain.  
 
To assess the heating potential the particles were diluted according to their iron 
content (see Table 3.3) to 1 mg Fe/ml in dH2O in microcentrifugation tubes.  For the 
measurement, a temperature probe was inserted through the lid of the tube and the 
sample inserted into the system before it was subjected to the alternating magnetic 
field (AMF) with 145 V and 0.92 A applied to the coil at 1.15 MHz and peak field 
amplitude of 13.5 kA/m.  
 
The temperature was recorded for 25 min resulting in a heating profile, as shown in  
Fig. 3.12. Afterwards the temperature probe was removed; the microcentrifugation 
tube sealed off and left to cool back to room temperature. This procedure was 
repeated twice (not shown in Fig. 3.12) for each sample resulting in three 
measurements per sample, from which the average and standard deviation were 
calculated (Fig. 3.13 and Table 3.4) 
 
 
Fig. 3.12 Heating profile of Ferucarbotran (1 mg Fe/ml). Starting at room temperature, after an 
initial increase in temperature, the heating slowed down before it stabilized at 62 °C. This 
heating profile represents a single measurement. 
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Fig. 3.13 Determined heating potentials of different nanoparticles (1 mg Fe/ml) after 25 min 
using the MACH system starting from 25 °C. The best heating potential was demonstrated by 
Ferucarbotran reaching a final temperature of 62 °C with a total temperature increase of  
37 °C. fM-DX 100 and fM-CMX 100 achieved temperatures above 50 °C, while fM-DX 50,  
nm-d-spio 100, nm-CLD-spio 100 and BNF-starch 100 did not reach hyperthermia 
temperatures. (For details see Table 3.4.) 
 
The heating profiles indicated that BNF-starch 100 was the worst heater on our 
system and confirmed its thermal blockage at room temperature. fM-DX 100 and fM-
CMX 100 both reached temperatures above 50 °C. However, Ferucarbotran 
demonstrated the best heating potential reaching 62 °C. 
 
Table 3.4 Determined heating potential of different nanoparticles at the concentration of  
1 mg Fe/ml after a starting temperature of 25 °C and 25 min in the MACH system, as shown in 
Fig. 3.13 
 
Sample Temp [°C] Std-Dev. [%] 
fM-DX 50 40.8 0.9 
fM-DX 100 54.5 0.8 
fM-CMX 100 53.4 1.1 
fM-DXS 100 45.0 1.1 
nm-D-spio 100 35.5 2.5 
nm-CLD-spio 100 36.6 1.1 
BNF-starch 100 29.8 0.7 
Ferucarbotran 62.0 0.6 
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Fig. 3.14 Determined heating potential of different concentrations of Ferucarbotran, between 
0-1 mg Fe/ml, after 25 min within the MACH system starting from 25 °C. 
 
Ferucarbotran was diluted further down and additional measurements were taken 
with 0.25, 0.5, and 0.75 mg Fe/ml (Fig. 3.14) and, even at 0.25 mg Fe/ml, a 
substantial temperature increase was recorded. 
 
Consequently, in order to be able to compare the heating potential of the 
nanoparticles with other nanoparticles tested in the literature, another set of 
hyperthermia experiments was performed using 1 ml of undiluted particles.  
 
Depending on the shape of the resulting heating profile, for curves the Box Lucas 
model or for more linear data linear fits were applied to calculate the commonly used 
specific absorption rate (SAR) and the intrinsic loss power (ILP) [See section: 
1.3.1.5].  
 
The ILP is a relatively new parameter introduced by Kallumadil et al. (Kallumadil, 
Tada et al. 2009) allowing the comparison of heating profiles using different magnetic 
field strengths and frequencies, as SAR does not account for that. 
 
The ILP values were calculated from the averaged temperature increases of the 
measurements and therefore no standard deviations are displayed in Fig. 3.15. 
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Fig. 3.15 Calculated ILP values for different nanoparticles (as shown in Table 3.5).  
 
Interestingly, comparing the actual heating data (see Fig. 3.13) with the calculated 
ILP values (Fig. 3.15), nm-D-spio 100 and nm-CLD-spio 100 should have heated 
better than fM-DX 100 and fM-CMX 100. Still, their ILP values (see Fig. 3.15 and 
Table 3.5) are very similar. In contrast the ILP value for BNF-starch 100 is even lower 
than the heating data would suggest.  
 
A comparison of the ILP values of nm-D-spio 100, BNF-starch 100 and Ferucarbotran 
(Resovist®) with the literature (Kallumadil, Tada et al. 2009) (see Table 3.5) shows 
that these values are comparable. However, the batch of Ferucarbotran tested in the 
experiments presented here seems to be more potent. 
 
Table 3.5 Calculated SAR and ILP values 
Sample SAR [W/g] ILP [nHm2/kg] 
ILP 
(Kallumadil, 
Tada et al. 
2009) 
fM-DX 50 104.25 0.92 - 
fM-DX 100 260.38 2.29 - 
fM-CMX 100 264.25 2.33 - 
fM-DXS 100 153.39 1.35 - 
nm-D-spio 100 279.83 2.46 3.12 
nm-CLD-spio 100 304.38 2.68 - 
BNF-starch 100 31.32 0.28 0.17 
Ferucarbotran 400.60 3.53 3.1 
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3.4 Discussion 
The aim of this study was to investigate the properties of eight commercially available 
nanoparticles and their heating potential to determine the most suitable candidate for 
therapeutic hyperthermia application. 
 
The first characteristic to be assessed was the hydrodynamic diameter and even 
though all MNP samples were acquired suspended in water, only three out of the 
eight nanoparticles investigated tested within an acceptable size range of ±5 nm 
around the specified hydrodynamic diameters.  In the case of fM-DX 100, the 
determined hydrodynamic diameter of 197 nm exceeded the intended size by 97 nm. 
Additionally, suspending the particles in 5 mM NaCl and PBS showed that  
fM-CMX 100 and fM-DXS 100 were not stable in the presence of salts. This made 
them unsuitable for in vitro or in vivo hyperthermia application, as aggregation affects 
the heating potential (Hergt, Dutz et al. 2008) 
 
The ζ-potentials of the particles were almost neutral, as dextran is not charged, 
except for Ferucarbotran with a ζ-potential of -23 mV, due to its carboxylated dextran 
coating (Reimer and Balzer 2003). This indicated the presence of carboxyl groups on 
the surface of Ferucarbotran a possible target for antibody attachment. 
 
Hydrodynamic diameter and ζ-potential are essential information for the fate of the 
nanoparticles in vivo (Mailander and Landfester 2009), while core size and structures 
as well its magnetic properties affect the heating potential of the nanoparticles 
(Gonzales-Weimuller, Zeisberger et al. 2009; Krishnan 2010; Ortega 2012).  
 
TEM analysis of the cores revealed a variety of core structures. Chemicell particles 
(fM-DX 50, fM-DX 100, fM-CMX 100 and fM-DXS 100) revealed spherical cores with 
similar core sizes and distributions, while the particles from Micromod demonstrated a 
different core structure for each particle sample. Whereas nm-d-spio 100 showed 
spherical cores similar to the Chemicell particles, nm-CLD-spio 100 resembled 
miniclusters rather than isolated spheres. TEM images of BNF-starch 100 revealed a 
cuboid core structure, containing some as big as 50 nm, indicating thermal blockage 
at room temperature and requiring strong magnetic fields to induce heating, which is 
consistent with the literature (Bordelon, Cornejo et al. 2011).  
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Magnetic property analysis of the particles using SQUID showed mainly 
ferromagnetic and superparamagnetic responses (Pankhurst, Connolly et al. 2003; 
Krishnan 2010). Unfortunately, the mass of the samples analysed was not recorded, 
and therefore the mass of the particles (emu/g) could not be corrected to enable 
direct comparisons. However, the determined MH curves did reveal hyperthermia 
potential in some particles, such as fM-DX 100, fM-CMX 100 and Ferucarbotran.  
 
Since MNP differ with regard to the coating to iron ratio, core composition and size, 
the atomic iron content was chosen as the common denominator to compare heating 
potentials. 
 
The atomic iron content determined by ICP-AES and most particles corresponded 
with specifications provided by the manufacturer. However, two particles, fM-DX 50 
and nm-D-spio 100, had a considerably lower iron content than the others. The 
reason for this can be found in the fact that fM-DX 50 had a substantially smaller 
overall hydrodynamic diameter and smaller iron oxide cores, resulting in an overall 
higher amount of coating present and a lower iron content.  
 
Hyperthermia experiments, where the particles were subjected to AMF starting at 
room temperature (20 °C), confirmed the results of the magnetic measurements 
regarding the heating potential of the different particles. Ferucarbotran demonstrated 
the best heating rate by reaching 62 °C, at a concentration of 1 mg Fe/ml. Even with a 
dose as low as 0.25 mg Fe/ml a temperature of 40 °C was reached. The Chemicell 
particles (fM-DX 50, fM-DX 100, fM-CMX 100 and fM-DXS 100) investigated also 
showed respectable heating potentials reaching temperatures between 40.8 °C (fM-
DX 50) and 54.5 °C (fM-DX 100). Micromod particles (nm-d-spio 100, nm-CLD-spio 
100 and BNF-starch) barely achieved 36.6 °C with their best heating candidate  
nm-CLD-spio 100. This result was consistent with the information gained from TEM 
and SQUID, but renders them unsuitable for in vivo hyperthermia application with the 
MACH system. 
 
A study by Bordelon et al. (Bordelon, Cornejo et al. 2011) compared BNF-starch,  
nm-d-spio and Feridex by subjecting them to AMF with magnetic field strengths 
between 8 – 97 kA/m with 650 V applied to the coil at 141 kHz. BNF-starch 
demonstrated substantial temperature increases subjected to magnetic field strengths 
between 32-90 kA/m, but at lower magnetic field strengths the results were consistent 
with our measurements obtained by using the MACH apparatus, providing 13.5 kA/m 
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at 1.15 MHz.  Looking at the ILP calculated from the data provided with 0.41 nHm2/kg 
is also consistent with our measurements 0.28 nHm2/kg considering the fact that 
Bordelon et al. used a monodisperse BNF-starch suspension slightly increasing its 
heating potential. 
 
All characterisation performed in this chapter established Ferucarbotran as lead 
candidate for hyperthermia application.  Ferucarbotran, unformulated Resovist®, 
originally developed as an MRI contrast agent for liver (Reimer and Balzer 2003) was 
soon discovered by the magnetic fluid hyperthermia community (Glockl, Hergt et al. 
2006; Hergt, Dutz et al. 2006) and due to its superior heating potential, which was 
topped only by bacterial magnetosomes (Hergt, Hiergeist et al. 2005; Hergt, Dutz et 
al. 2006). Ferucarbotran has been used as standard ever since in magnetic fluid 
hyperthermia (Kallumadil, Tada et al. 2009; Thomas, Dekker et al. 2009), but also in 
the development of new techniques like magnetic particle imaging (Gleich and 
Weizenecker 2005; Pankhurst, Thanh et al. 2009) 
 
 
3.5 Summary 
The aim of this study was to determine the most suitable iron oxide nanoparticles for 
hyperthermia application. 
 
Eight different commercial magnetic iron oxide nanoparticles were analysed with 
regard to their hydrodynamic diameter, core size and structure, atomic iron content, 
magnetic properties and their heating potential determined. 
 
Overall analysis established Ferucarbotran as the leading candidate and therefore it 
was taken forward for functionalisation.  
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Chapter 4 
 
 
 
 
 
 
 
 
 
 
 
4 Functionalising Nanoparticles with scFv 
Antibody Fragments and Characterising 
Their Targeting Ability by Quartz Crystal 
Microbalance 
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4.1 Introduction 
In the previous chapter Ferucarbotran was established as the best candidate for 
hyperthermia application through thorough property analysis of commercially 
available nanoparticles. In order to enable targeting, the aim of the work described in 
this chapter was to develop a method to successfully functionalize Ferucarbotran with 
scFv antibody fragments.  
 
The two main scFv antibody fragments used in this thesis were shMFEm and its non-
binding variant shNFEm. Both were derived from MFE-23, scFv specifically targeting 
the N and A1 domains of the carcinoembryonic antigen (CEA) (Boehm, Corper et al. 
2000; Sainz-Pastor, Tolner et al. 2006). 
 
CEA, a cell surface glycoprotein, was first described by Gold and Freedman (Gold 
and Freedman 1965) and is overexpressed in a number of different cancers, such as 
colorectal, lung, breast and stomach cancer, making it a prime target for antibody-
directed therapy (Bates, Luo et al. 1992; Hammarstrom 1999).  
 
MFE-23 was selected from a phage display library of anti-CEA scFvs constructed 
from variable region genes extracted from mice immunized with CEA (Chester, 
Begent et al. 1994). It has been extensively characterised (Chester, Mayer et al. 
2000) and was the first murine scFv antibody fragment tested in the clinic allowing 
radioimmunodetection of colorectal adenocarcinoma (Meyer, Gaya et al. 2009). 
Additionally MFE-23 has also been investigated and used as part of the antibody-
directed prodrug therapy (ADEPT) (Napier, Sharma et al. 2000; Mayer, Francis et al. 
2006; Andrady, Sharma et al. 2011). 
 
Since the negative ζ-potential of Ferucarbotran measured in the previous chapter 
suggested the presence of carboxyl groups on its surface, carbodiimide conjugation 
was the first to be evaluated. Thereby the scFv is covalently linked to the carboxyl 
groups within the dextran, through amines, provided by lysines present throughout 
the protein. 
 
Consequently, procedures to purify the FX-scFv conjugates and to confirm the 
attachment of the scFv to Ferucarbotran were investigated, after which, quartz crystal 
microbalance (QCM) was explored to determine the functionality of the conjugate. 
 
  66 
4.2 Objectives 
The objectives of the research described in this chapter were to: 
1. Functionalise Ferucarbotran with scFv antibody fragments 
2. Establish method to purify the generated FX-scFv conjugates 
3. Develop method to assess the functionality of the FX-scFv conjugates 
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4.3 Results 
4.3.1 Conjugation of scFv Antibody Fragments to Ferucarbotran 
4.3.1.1 Characterisation of scFv antibody fragments 
shMFEm and shNFEm have been expressed in Pichia pastoris and were kindly 
provided by Dr. Berend Tolner (UCL Cancer Institute). SDS-PAGE followed by 
Coomassie staining and ELISA confirmed the purity, size, and immunoreactivity to 
CEA of shMFEm and shNFEm (Fig. 2.1). shNFEm does not bind to CEA and it is the 
ideal negative control, as it only differs from shMFEm by one amino acid. 
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Fig. 4.1 shNFEm and shMFEm were tested for purity and binding to CEA. (A) Coomassie stained 
20-4% gradient Tris glycine SDS-PAGE gel, shows the purity and size equality of shMFEm and 
shNFEm. (B) CEA ELISA of shMFE and shNFEm using a mouse anti-His primary antibody 
followed by a sheep anti-mouse HRP indicates shNFEm does not bind to CEA. To prove the 
presence of shNFEm, another ELISA (C) was performed, where both scFvs were immobilized 
directly on a 96-well plate and detected with a mouse anti-His antibody, followed by sheep anti-
mouse HRP. In both ELISA PBS was used as negative control. 
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4.3.1.2 Stability of Ferucarbotran in Physiological Buffers 
In the previous chapter (see section: 3.2.1), it was found that fM-CMX and fM-DXS 
particles were not stable in PBS and 5 mM NaCl solution, showing that different 
conditions can affect particle stability. This is especially important during conjugation 
as different buffers and pH are used, potentially altering their stability.  Therefore, 1.5 
mg Ferucarbotran were added to different microcentrifugation tubes containing 1.5 ml 
dH2O (pH 6.4), saline (pH 7.4), PBS (pH 7.2) and 0.1 M sodium phosphate buffer  
(pH 8) and (pH 8.5). After 24 hrs at room temperature, the particles were put into 
Dynal magnetic particle concentrator for 15 min and a picture taken. This was 
repeated after 1 and 2 weeks (Fig 2.2). 
 
No change in stability could be observed after 24 hrs. One week later some 
precipitation was recorded in the 0.1 M sodium phosphate buffers. Substantially more 
precipitation was noted for both Ferucarbotran suspended in saline and PBS, 
whereas the FX suspension in dH2O was stable.  
 
After two weeks, precipitation was observed in all buffers, except for dH2O, which 
showed minimal precipitation. PBS appeared to cause the greatest effect on 
precipitation, as the change in colour indicates that most of the particles are within the 
precipitate. 
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Fig. 4.2 Stability of Ferucarbotran (FX) in different buffers over the course of 2 weeks. After  
24 hrs, little precipitation was observed with FX in PBS. A week later, almost all samples 
showed amounts of precipitation with substantial precipitation in PBS and saline and minimal 
precipiation in all other buffers. After two weeks, every sample showed considerable 
precipitation. The least amount of precipitation was observed in dH2O. 
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4.3.1.3 Carbodiimide Conjugation of shMFEm to Ferucarbotran 
The negative ζ-potential of Ferucarbotran, shown in the previous chapter, indicated 
the presence of carboxyl groups available for conjugation. Therefore carbodiimide 
conjugation chemistry represented schematically in Fig. 2.3 and detailed in 1.4.2 was 
investigated. 
 
 
Fig. 4.3 Schematic representation of carbodiimide chemistry using 1-ethyl-3-(3-
dimethylaminopropyl) carbodiimide (EDC) and N-hydroxysuccinmide (NHS). 
 
To establish and optimise this conjugation method fM-CMX, iron oxide nanoparticles 
covered in carboxymethylated dextran were used, as this coating provides multiple 
carboxyl groups for attachment, compared to FX. However, as fM-CMX are not stable 
in PBS, the preferred buffer for the carbodiimide reaction. The stability of fM-CMX in 
0.1 sodium phosphate buffer at pH 7.4 was tested. As the particles stayed in 
suspension over the course of a couple of days, a conjugation protocol to attach 
shMFEm to fM-CMX was established.  
 
With the knowledge obtained about the stability of FX in PBS (see section: 4.3.1.2), 
the carbodiimide conjugation protocol for fM-CMX was applied. Although minimal 
precipitation was shown at 24 hrs for non-conjugated FX, shMFEm conjugated FX 
started to precipitate 2 hrs after the conjugation.  A week later, most of the conjugated 
FX had dropped out of solution suggesting that the conjugation chemistry destabilized 
the nanoparticles. 
 
4.3.1.4 Cyanogen Bromide Conjugation of shMFEm to Ferucarbotran 
As the conjugation to carboxyl groups destabilised the Ferucarbotran, a different 
conjugation chemistry utilizing hydroxyl groups was investigated: cyanogen bromide 
conjugation (Hermanson 2008), shown schematically in Fig 2.4. 
+EDC/NHS mix 
(via O-acylisourea) + 
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Fig. 4.4 Schematic representation of cyanogen bromide conjugation. 
 
After conjugation, in contrast to the carbodiimide conjugation, the particle suspension 
seemed stable, little precipitation was observed. The conjugates were still stable a 
week after the conjugation. This method was therefore far superior to carbodiimide 
chemistry and the first successful functionalisation of FX. 
 
 
4.3.2 Purification of FX-scFv Conjugates 
4.3.2.1 Size Exclusion Chromatography 
Concentrated Ferucarbotran behaves as a ferrofluid due to the superparamagnetic 
behaviour of the single domain core crystals. However, when the particles are diluted 
with buffer, as it is the case during conjugation, the distance between the cores 
increases, the magnetic interactions become weaker. Therefore, stronger magnetic 
field gradients are required to enable magnetic washing. These gradients cannot be 
achieved through magnetic separators, like the Magna-Sep™ (Invitrogen). More 
sophisticated, time consuming and expensive methods, like a High Gradient Magnetic 
Separator (Miltenyi), are required. Additionally the mass of the single particles is too 
small to be concentrated by centrifugation. Hence different purification methods were 
investigated.  
 
One commonly used method to purify particles is dialysis, where molecules are 
separated by diffusion, driven by different concentrations of molecules on either side 
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of a membrane. It is a time consuming and expensive method, but, most importantly, 
unwanted substances are not effectively eliminated and only merely diluted out, which 
does not enable adequate analysis of the conjugates.  
 
An alternative method found in the literature was size exclusion chromatography 
(SEC) (Tiefenauer, Kuhne et al. 1993; Kresse, Wagner et al. 1998; Lutz, Stiller et al. 
2006). To establish a suitable SEC protocol for the purification of Ferucarbotran 
different column matrix (Fig. 2.5-6) and lengths (Fig. 2.7-10) were scrutinized. 
 
Fig. 4.5 Ferucarbotran trapped in a column for size exclusion chromatography, HiPrep™ 
16/60 filled with Sephacryl™ S-300 High Resolution matrix. 
 
Unconjugated FX loaded onto a SEC column filled with Sephacryl™ S-300 High 
Resolution matrix showed that the particles were irreversibly trapped within the 
column (Fig. 4.5). 
 
 
Fig. 4.6 Ferucarbotran moving through a PD-10 desalting column filled Sephadex™ G-25 and 
equilibrated with PBS during a cyanogen bromide conjugation. 
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During the conjugation process, in order to remove the excess cyanogen bromide, the 
activated particles were applied to a PD-10 desalting column filled with Sephadex™ 
G-25, a dextran matrix where the particles were able to move through easily (Fig. 
4.6). Therefore Sephadex™ was investigated as separation matrix. Due to the size of 
shMFEm and shNFEm of 27 kDa, Sephadex™ G-100 was chosen instead of 
Sephadex™ G-25, with a fractionation range for globular proteins between 4 – 150 
kDa. 
 
Using the ÄKTA prime system an empty XK 16/70 column was packed with 
Sephadex™ G-100. To assess the quality of the packing and also to determine the 
volume after which the proteins leaves the column, a gel filtration protein standard 
was applied to the column and the SEC profile recorded (Fig. 4.7) 
 
 
Fig. 4.7 SEC profile of gel filtration protein standard running through a XK 16/70 column filled 
with Sephadex™ G-100 at flow rate 0.5 ml/min in PBS elution buffer. Proteins bigger than 100 
kDa, the purification limit of Sephadex™ G-100, come off the column in the ‘void’ marking the 
big peak after the first 35 ml buffer passed through the column. The little distance and overlap 
between peaks indicates the need for a longer column to gain a better resolution. This SEC 
profile represents a single measurement. 
 
Consequently, in a second run, 1 ml PBS containing 5 mg unconjugated 
Ferucarbotran were applied to the column to determine the location and width of the 
particle peak (Fig. 4.8). It was found that the particles were trailing into the range 
where the scFv fragments were expected to leave the matrix. Therefore, in order to 
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achieve a clear separation between conjugate and free antibody, a longer column 
length had to be chosen.  
 
Fig. 4.8 SEC profile of Ferucarbotran running through a XK 16/70 column filled with 
Sephadex™ G-100 at flow rate 0.5 ml /min in PBS elution buffer. Ferucarbotran came off the 
column as part of the void, as it is bigger than 100 kDa, the purification limit of Sephadex™ G-
100. This SEC profile represents a single measurement. 
 
An XK 16/100 column was packed with Sephadex™ G-100 and the applied gel 
filtration standard (Fig. 4.9) revealed a clearer separation of the proteins and an 
expected peak for shMFEm after about 125 ml. Another run of unconjugated 
Ferucarbotran (Fig. 4.10) showed that the majority of particles were leaving the matrix 
after 70 – 90 ml elution buffer. So for the first run of Ferucarbotran functionalized with 
shMFEm (FX-shMFEm) only fractions between 70 – 85 ml were collected (Fig. 4.11) 
preventing an overlap with free scFv.  
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Fig. 4.9 SEC profile of gel filtration protein standard running through a XK 16/100 column filled 
with Sephadex™ G-100 at flow rate 0.5 ml /min in PBS elution buffer. Proteins bigger than 
100 kDa, the purification limit of Sephadex™ G-100, come off the column in the ‘void’ marking 
the big peak after the first 70 ml buffer passed through the column. The distinct peaks 
indicated that the column was well packed and ready to purify samples. This SEC profile 
represents a single measurement. 
 
 
 
Fig. 4.10 SEC profile of Ferucarbotran running through a XK 16/100 column filled with 
Sephadex™ G-100 at flow rate 0.5 ml /min in PBS elution buffer. Ferucarbotran came off the 
column as part of the void, as it is bigger than 100 kDa, the purification limit of Sephadex™ G-
100. This SEC profile represents a single measurement. 
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Fig. 4.11 SEC profile of purified FX-shMFEm conjugates. To avoid contamination of the 
conjugates with unbound shMFEm, only fractions between 70 – 85 ml were collected and 
pooled. The inset shows a magnified view of the base of the conjugate ‘void’ peak (blue line), 
with the collected conjugate fractions with 20 ml volume ‘distance’ to the shMFEm elution 
peak (red line) 
 
4.3.2.2  Concentration of the Purified FX-scFv Conjugate Pool 
After eluting off the SEC column, the concentration of the conjugates was below  
0.5 mg/ml, so a method to re-concentrate them had to be established. Millipore 
Amicon Ultra-4 centrifugal filter units and Millipore Centriprep YM-50 were 
investigated.  
 
Amicon Ultra-4 centrifugal filter units were not suitable, as particles got stuck to the 
filter, which resulted in a considerable loss of conjugate, whereas the Centriprep YM-
50 filter membrane did not interact with particles minimalizing the loss of conjugate. 
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4.3.2.3 Determining the Purity of FX-scFv Conjugates 
To demonstrate the purity of the FX-scFv conjugates, a western blot (Fig 2.12) was 
performed.  
 
          
Fig. 4.12 Western blot using an anti-His Ab showing samples of purified FX-shMFEm and FX-
shNFEm conjugates. In all functionalised particle samples a smear from the particles can be 
seen as well as faint band at the same size of the scFv. 
 
The faint bands in the western blot (Fig. 4.12) suggested that the purification was not 
successful. However dissection of the procedure leading to this western blot indicated 
a different cause for the bands. Samples had been boiled for 4 min at  
90 °C under reducing conditions before they were applied on a precast SDS-PAGE 
gel, which could have destroyed the link between particle and scFv. Therefore a 
native PAGE gel was cast and samples from the same conjugation experiments were 
run without boiling and under non-reducing conditions followed by an ECL western 
blot (Fig. 4.13).  
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Fig. 4.13 ECL western blot using an anti-His Ab showing samples of the FX-shMFEm and FX-
shNFEm conjugates before and after purification. Both unpurified samples show a band at the 
same size as the corresponding scFv, while no bands at this size were observed. Controls 
indicate no interaction of anti-His Ab with the FX on its own, demonstrating successful 
purification. 
 
In the unpurified samples, a smear from the particles can be seen as well as faint 
band at the same size of the scFv. Purified samples show the conjugates stuck at the 
top of the gel and controls confirm that nanoparticles without scFv attached to their 
surface cannot be detected by an anti-His Ab. 
 
 
4.3.3 Characterisation of FX-scFv Conjugates 
4.3.3.1 Antibody Presence of FX-scFv conjugates 
After successful purification and concentration of the conjugates, ELISA confirmed 
the presence of scFv on the suface of the FX-scFv, where the conjugates and the 
corresponding controls were directly immobilized on a 96-well MaxiSorp™ plate and 
consequently treated with an anti-His or anti-dextran antibody. It is important to point 
out that MaxiSorp™ (according to the manufacturer’s homepage (Nunc)) is a modified 
polystyrene surface with high affinity to polar groups and therefore proteins.  
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Fig. 4.14 Determination of the presence of scFv on FX-scFv conjugates by ELISA. FX-
shMFEm and FX-shNFEm were immobilized directly on a 96-well MaxiSorp™ plate (Nunc) 
and detected with a mouse anti-His or mouse anti-dextran antibody, followed by sheep anti-
mouse HRP. PBS was used as negative control. 
 
A closer look at the anti-dextran results in Fig. 4.14 show that substantially more 
particles can be detected in the conjugate carrying lanes, than in the pure FX lane, as 
the attached protein within the coating allows the particles to interact better with the 
MaxiSorp™ plate confirming the presence of scFv on the particles.  
 
4.3.3.2 Binding Affinity of scFv and SPION-scFv 
To determine the binding affinity of the conjugated antibody fragments quartz crystal 
microbalance (QCM), in collaboration with Attana SA, was explored. 
 
In the first set of experiments, the binding kinetics of shMFEm and shNFEm were 
determined, by immobilising the scFvs onto two carboxyl sensor chips. Consequently, 
the sensor chips were treated with different concentrations of the cognate antigen 
NA1, resulting in the interaction profiles shown in Fig. 4.14. This clearly showed NA1 
binding to shMFEm, while barely any interacting with shNFEm.  
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Fig. 4.15 (A) Interaction profile of immobilized shMFEm with different concentrations of NA1 
ranging from 3.1 to 50 ng/ml. (B) Reference chip carrying shNFEm subjected to the same 
concentrations of NA1. While each black line indicates a single measurement, each red line 
represent the best calculated fit for this particular concentration.  
 
Next the two conjugates FX-shMFEm and FX-shNFEm were immobilised on two 
polystyrene sensor chips and treated with the same concentrations of NA1 ranging 
from 6.2 to 50 ng/ml.  
 
The resulting interaction profiles (Fig. 4.15) also showed that the NA1 was binding to 
the FX-shMFEm conjugate, while only little interaction with the negative control, the 
FX-shNFEm conjugate. The little interaction observed could be due to mass transfer, 
as 50 ng NA1 is quite a high concentration in a QCM experiment (Personal comment 
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for reasonings derived from conversation with Attana application specialists Liselotte 
Kaiser and Staffan Grenklo).  
 
 
Fig. 4.16 (A) Interaction profile of captured FX-shMFEm conjugates subjected to different 
concentrations of NA1 ranging from 6.2 to 50 ng/ml. (B) Reference channel showing the 
interaction profile of FX-shNFEm conjugate with NA1. While each black line indicates a single 
measurement, each red line represent the best calculated fit for this particular concentration. 
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Table 4.1 Key values describing the interactions from Fig. 4.15 and Fig. 4.16 
 shMFEm FX-shMFEm 
Association rate constant ka [M-1 s-1] 9.07E+3 ±2 7.31E+3 ±6 
Dissociation rate constant kd [s-1] 4.01E-4 ±3E-6 7.01E-4 ±8E-7 
Dissociation constant KD [M] 4.42E-8 ±3E-10 9.6E-8 ±1E-10 
 
The association rate constant, ka, in Table 4.1 shows that antigen is attaching to the 
scFv on the particles at a slightly slower rate compared to the native scFv, while in 
contrast the dissociation is almost twice as fast resulting in a significantly lower 
binding affinity.  
 
4.3.4 Site-specific attachment of shMFEm to Ferucarbotran 
Additionally to carbodiimide and cyanogen bromide conjugation another attachment 
route was investigated: site-specific attachment. 
 
Carbodiimide and cyanogen bromide conjugation chemistries both aim to attach a 
protein via available amine groups found throughout the structure (Fig 4.17), in 
contrast to site-specific attachment utilizing a functional group found only once within 
the structure in a particular location, such as a cysteine tag. 
 
 
Fig. 4.17 Structure of MFE-23 (Boehm, Corper et al. 2000). Available amines provided through 
lysines were highlighted in blue, while yellow, orange, and green represent complementary 
determining regions (CDR). This illustrative model was kindly provided by Paul. J. Gane. 
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4.3.4.1 shMFEm-Cys 
To enable site-specific attachment, a cysteine tag was engineered into the structure 
of shMFEm. shMFEm-Cys has been expressed in Pichia pastoris and was kindly 
provided by Dr. Berend Tolner (UCL Cancer Institute).  
 
The profile from the protein purification by the size exclusion chromatography  
(Fig. 4.18) showed two peaks, which were collected separately as Pool 1 and 2 
indicated in the figure. 
 
 
Fig. 4.18 SEC profile of shMFEm-Cys showing two peaks suggesting the presence of dimers 
and monomers. Fractions 6-9 ml were combined as Pool 1, while fractions 15-19 ml were 
combined as Pool 2. This SEC profile represents a single measurement. 
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Since multiple peaks often indicate dimerization, samples from both pooled scFv 
fractions were run on an SDS-PAGE followed by Coomassie staining (Fig. 4.19). 
 
Fig. 4.19 Pooled fractions taken from different SEC peaks were tested for puritiy by a 
Coomassie stained 4-20% gradient Tris glycine SDS-PAGE gel under reducing and non-
reducing conditions. shMFEm was used a positive control. The thick band of Pool 1 at around 
50 kDa under non-reducing conditions indicated that the these pooled fractions mainly 
consisted of dimer, while the band of pool 2 around 27 kDa suggested primarily monomers. 
 
 
4.3.4.2 Site-specific attachment of shMFEm-Cys to Ferucarbotran 
In order to conjugate shMFEm-Cys via its cysteine tag, two conjugation chemistries 
had to be combined. First, sodium periodate chemistry was used to attach the 
maleimide linker BMPH to Ferucarbotran and, in a second conjugation step, the 
maleimide reacted with the available cysteine within shMFEm-Cys forming a thiol 
bond. 
 
For attachment of the maleimide linker 10 mg sodium periodate were dissolved in  
800 ul of a 50 mM sodium borate buffer (pH 8.5). 10 mg Ferucarbotran nanoparticle 
suspension were added and incubated on the roto-torque for 25 min at room 
temperature wrapped in foil, as this step is light sensitive. To stop the reaction and 
remove the excess sodium periodate the particles were run through the PD-10 
equilibrated with 50 mM sodium borate buffer. The particles were collected in a fresh  
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2 ml micro centrifugation tube before immediately 10 mg maleimide linker BMPH 
were added and suspended in the particle mix. The mix was incubated on the roto-
torque for two hours before 200 µl of 5 M sodium cyanoborohydride in 1 M NaOH 
were added. Consequently, the suspension was incubated o/n on the roto-torque at 
RT.  On the next day, 100 µl of a 0.1 M glycine in 50 mM sodium borate buffer (pH 
8.5) solution were added and the mix incubated for another hour on the roto-torque in 
order to block the unreacted sites. 
 
The maleimide was activated, by running the particle mix through a PD-10 column 
equilibrated with 50 mM sodium borate buffer (pH 7). 100 µg shMFEm-Cys were 
added to the nanoparticles and mixture incubated on the roto-torque o/n. 
Subsequently 100 µl of a 0.1 M cysteine in 50 mM sodium borate buffer (pH 8.5) 
solution were added and the mix incubated for another hour on the roto-torque before 
it was stored for purification and analysis at 4 °C. 
 
4.3.4.3 Purification of the FX-shMFEm-Cys 
The FX-shMFEm-Cys conjugates were concentrated using a Centriprep YM-50 and 
purified by size exclusion chromatography, as shown in Fig. 4.20. 
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Fig. 4.20 SEC profile of FX-shMFEm-Cys running through a XK 16/100 column filled with 
Sephadex™ G-100 at flow rate 0.5 ml /min in PBS elution buffer. FX-shMFEm-Cys came off 
the column as part of the void, as it is bigger than 100 kDa, the purification limit of 
Sephadex™ G-100. Fractions were collected between 55 – 65 ml elution volume to avoid 
contamination with the unbound shMFEm-Cys. This SEC profile represents a single 
measurement. 
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The collected fractions were again concentrated using a Centriprep YM-50 before 
their purity was evaluated by SDS-PAGE followed by ECL western blot (Fig. 4.21) 
 
 
 
Fig. 4.21 ECL western blot using an anti-His Ab showing FX-shMFEm-Cys before (1) and after 
(2) purification with shMFEm-Cys (3) and unconjugated FX (4) as controls. SDS-PAGE was 
performed using 4-20% gradient Tris glycine gel for this western blot. This explains the long 
particle smears seen in lane 1 and 2, as FX is not a monodisperse particle suspension. A 
clear band can be seen in lanes 1 and 3, but not in lane 2 indicating a successful purification. 
 
 
4.3.4.4 Analysis of FX-shMFEm-Cys Conjugates 
After successful purification and concentration of the conjugates, ELISA confirmed 
the presence of shMFEm-Cys on the surface of the FX-shMFEm-Cys conjugates. For 
this ELISA, conjugates and corresponding controls were directly immobilized on a 96-
well MaxiSorp™ plate and consequently treated with an anti-His or anti-dextran 
antibody (see section: 4.3.3.1). 
kDa 
250 
148 
98 
64 
50 
36 
22 
     1     2      3     4 
  88 
 
Fig. 4.22 Determination of the presence of scFv on the surface of the FX-scFv conjugates by 
ELISA. FX-shMFEm and FX-shNFEm were immobilized directly on a 96-well maxisorp plate 
and detected with a mouse anti-His antibody or mouse anti-dextran antibody, followed by 
sheep anti-mouse HRP. PBS was used as negative control. 
 
In Figure 4.22, the anti-His antibody confirmed the presence of shMFEm-Cys on the 
surface of Ferucarbotran. However, a closer look at the anti-dextran results in the 
same figure showed only slightly more particles were detected in the conjugate 
carrying lane, than in the pure FX lane (detected with the anti-DX antibody). As the 
attached protein within the coating allows the particles to interact better with the 
MaxiSorp™ plate, the FX-shMFEm-Cys conjugates should have bound better in 
comparision to the pure FX yielding a higher signal. 
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4.4 Discussion 
This chapter investigated the stable functionalisation of Ferucarbotran with scFv 
antibody fragments shMFEm and shNFEm. Different conjugation chemistries and 
strategies were evaluated. The FX-scFv conjugates were purified, concentrated, and 
analysed for their targeting ability. 
 
In the previous chapter, in order to determine the hydrodynamic diameter and  
ζ-potential, particles were suspended for a short amount of time in dH2O, PBS, and 5 
mM NaCl. Even though the particles were analysed immediately after suspension in 
the different buffers, it was shown that some particles (fM-CMX and fM-DXS) were 
not stable in PBS or 5 mM NaCl. While no immediate precipitation was observed with 
Ferucarbotran, for any applications these particles might have to be stored for at least 
week. Therefore, stability of Ferucarbotran in dH2O (pH 6.4), saline (pH 7.4), PBS  
(pH 7.2), and 0.1 M sodium phosphate buffer (pH 8 and pH 8.5) was examined.   
Although no change in stability could be observed after 24 hrs, after one week minor 
precipitation was recorded in the 0.1 M phosphate buffer samples and considerably 
more precipitation in PBS. One week later, precipitation was observed in all buffers, 
with the most precipitate in the PBS samples and the least in dH2O.  These results 
lead to the conclusion that Ferucarbotran should be stored in dH2O or 0.1 M 
phosphate- buffer, but PBS, as a storage buffer should be avoided, if possible. 
 
Since the negative ζ-potential of Ferucarbotran (-23 mV) in the previous chapter 
indicated the presence of carboxyl groups, carbodiimide chemistry (DeNardo, 
DeNardo et al. 2005) was the first to be investigated for the attachment of shMFEm 
and shNFEm to Ferucarbotran.  
 
Carboxyl groups on the nanoparticles are activated by the addition of  
1-ethyl-3-(dimethylaminopropyl)carbodiimide (EDC) to form an O-acylisourea 
intermediate, which then reacts with accessible amines provided by lysines within the 
structure of an antibody or scFv antibody fragment. The reaction efficiency of this 
process is improved through the addition of N-hydroxysuccinimide (NHS), which 
stabilises the O-acylisourea intermediate through the formation of a succinimide 
ester. (Hermanson 2008) 
 
 
  90 
First, experiments with Ferucarbotran using this chemistry showed a substantial 
amount of precipitation indicating that the carbodiimide conjugation destabilised the 
nanoparticle itself. This result suggested that some of the carboxydextran chains of 
Ferucarbotran were attached to the iron oxide core; the EDC/NHS chemistry activates 
these carboxylic groups and therefore destabilizes the nanoparticle. 
 
Consequently, a different conjugation chemistry utilizing hydroxyl groups within the 
dextran chains was examined: cyanogen bromide conjugation (Hermanson 2008). A 
nucleophilic elimination attack of the hydroxyl group on the cyanogen bromide results 
in cyanate ester and bromide. This is followed by a nucleophilic addition of the amine 
to electron deficient cyanide group resulting in an isourea linkage (Kozissnik 2012). 
Using this chemistry to functionalise Ferucarbotran with shMFEm and shNFEm 
resulted a stable particle suspension, where only little precipitation was observed. 
 
In order to enable characterization of the FX-shMFEm conjugates, the particles had to 
be separated from the unbound scFv antibody fragment and so different purification 
techniques were investigated. Ferucarbotran cannot be washed magnetically or by 
centrifugation requiring a different approach. In the literature, the most commonly 
presented method to purify particles is dialysis (Xie, Gu et al. 2005; Chandran, 
Chaudhary et al. 2006; Nash, Lai et al. 2010; Thomassen, Aerts et al. 2010), where 
particles are separated by diffusion. It is a time consuming and expensive method 
and does not provide elimination of the unwanted substances, as it is merely a 
dilution. 
 
Another method described in the literature was size exclusion chromatography (SEC) 
(Tiefenauer, Kuhne et al. 1993; Kresse, Wagner et al. 1998; Lutz, Stiller et al. 2006). 
To establish a suitable purification protocol for the FX-shMFEm and FX-shNFEm, 
conjugates different matrix and column lengths were investigated. A first experiment 
by applying unconjugated Ferucarbotran on a HiPrep™ column filled with 
Sephacryl™ S-300 high resolution matrix failed as the particles were irreversibly 
trapped within the column.  
 
Since, during conjugation, change of particles buffers was required, it was observed 
that Ferucarbotran easily travelled through a PD-10 desalting column filled with 
Sephadex™ G-25. So a Sephadex™ matrix was the next to be examined.  Due to the 
size of shMFEm and shNFEm with 27 kDa, Sephadex™ G-100 was chosen instead 
of Sephadex™ G-25, with a fractionation range for globular proteins between  
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4 – 150 kDa.  Next different column lengths were evaluated and the optimal setup for 
Ferucarbotran was found in XK 16/100 column filled with Sephadex™ G-100.  
 
In order to confirm that SEC was suitable to separate the FX-shMFEm and FX-
shNFEm from the unbound scFv antibody fragments, a Western blot was performed. 
However, the SDS-PAGE, under standard reducing conditions followed by a Western 
blot with an anti-His antibody, showed clear bands in purified and unpurified samples 
indicating the presence of unbound scFv, suggesting that purification had failed. 
Thorough dissection of the procedure leading to the respective Western blot found 
that since the samples had been boiled for 4 min at 90 °C under reducing conditions, 
this could have destroyed the link between particle coating and scFv. Therefore, a 
native PAGE gel was cast and samples from the same conjugation were run without 
boiling and under non-reducing conditions followed a by a slightly more sensitive ECL 
western blot. The results confirmed successful purification through SEC enabling 
characterization of the FX-shMFEm and FX-shNFEm conjugates. 
 
In 2009, Vigor et al. (Vigor, Kyrtatos et al. 2009) proposed the use of an ELISA to 
confirm the presence and immunoreactivity of antibodies on nanoparticles. The wells 
are coated with the antigen, particles are added and the antibodies detected with 
specific antibodies. In their experiment they used PEG and dextran coated 
nanoparticles, which have a neutral surface charge.  
 
However, a first experiment with Ferucarbotran showed high non-specific interaction 
of the particle with the polystyrene 96-well plate. Therefore Vigor’s method was 
slightly modified and the nanoparticles directly immobilized onto a 96-well MaxiSorp™ 
plate.  It is important to point out that MaxiSorp™, according to the manufacturer’s 
homepage (Nunc), is a modified polystyrene surface with high affinity to polar groups 
and therefore proteins. Hence, nanoparticles with functionalised with antibodies or 
antibody fragments were “sticking” better to the plate and therefore yield a more 
intense signal, then the unconjugated particles. 
 
Using this technique, it was confirmed that antibodies were bound to the surface of 
the nanoparticle, however, since there was no interaction with the antigen, no 
conclusion about the immunoreactivity of the FX-scFv conjugates could be drawn.  
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When characterising antibodies, binding kinetics (Malmborg, Michaelsson et al. 1992) 
are an important part and often determined through surface plasmon resonance 
(SPR) (Boozer, Kim et al. 2006) or quartz crystal microbalance (QCM) (Guilbault and 
O'Sullivan 1999).  SPR is a purely optical technique. Polarized light is shone through 
a prism onto a sensor surface with a gold film on which the sample ligand is 
immobilized. An optical detection unit senses the reflected light. When an analyte 
interacts with the immobilized ligand, there is a change of mass causing a change in 
the refraction or resonance (angle) and therefore in the recorded signal. (Jonsson, 
Fagerstam et al. 1991; Myszka 1997; Myszka 2000) 
 
QCM is based on the piezoelectric effect. An electric charge is applied to a quartz 
crystal inducing mechanical stress and causing it to oscillate at a specific frequency. 
A change of mass on the crystal’s surface initiates a change in frequency. This non-
optical technique enables the investigation of thicker layers like nanoparticles or even 
cells. (Guilbault and O'Sullivan 1999; Cooper and Singleton 2007) 
 
In the first set of QCM experiments, the scFv, shMFEm and shNFEm, were directly 
immobilized onto two sensor chips and subjected to different concentrations of NA1. 
The interaction profiles showed a clear interaction between shMFEm and NA1, while 
on the control channel with shNFEm almost no interaction was detected. 
 
Next the conjugates were directly immobilized onto two sensor chips and treated with 
the same concentrations of NA1 as the pure scFv, enabling the first visualisation of 
the interaction between a SPION-scFv conjugate and cognate antigen in real-time. 
Quartz crystal microbalance has been combined with nanoparticles in the past, 
however the nanoparticles were mainly used as signal enhancers to amplify the 
signal and therefore improve the sensitivity of this technique. (Lin, Zhao et al. 2000; 
Mao, Yang et al. 2006; Kim, Baek et al. 2007) 
 
The interaction profiles gained from the FX-scFv conjugates showed a significantly 
weaker interaction between the shMFEm functionalized conjugates and the NA1. 
Additionally, the binding kinetics revealed a slightly slower association rate, in 
comparison with the pure shMFEm results and an almost twice as fast dissociation 
rate.  An explanation for this phenomenon can be found in the different paths of the 
NA1 in both cases. While the pure scFv immobilized on the chip provide a planar 
surface with multiple interaction points for the cognate antigen, the conjugates with 
their spherical shape and dextran coat offer a much more difficult geometry for the 
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NA1 to interact with the attached shMFEm. Some scFv molecules might only be 
partially accessible due to the particle shape, but also due to physical hindrance, 
caused by the flexible dextran matrix (Livney, Ramon et al. 2001) shifting and partially 
covering the rather small scFv. 
 
A solution to this issue could be the use of iron oxide nanoparticles with a more 
stealth coating such as polystyrene or PEG or site-specific attachment of the targeting 
moiety (Kozissnik 2012).  Whereas conventional conjugation techniques, such as 
carbodiimide chemistry, establish covalent bonds randomly between any available 
carboxyl and amine group, site-specific attachment uses a unique target, such as a 
tag, in a specific location within the target molecule to create a single connection. The 
advantage site-specific attachment, over the random attachment, is that the 
orientation of the conjugated antibody or targeting moiety is known ensuring its 
functionality.  Therefore, site-specific attachment was also investigated as an option 
to functionalize Ferucarbotran with shMFEm. To realise this specific conjugation 
method, two chemistries were combined: Sodium periodate conjugation and 
maleimide chemistry.  
 
Using sodium periodate, the maleimide linker BMPH was attached to the 
Ferucarbotran, utilizing the primary hydroxyl groups within the dextran and the one 
amine group within the linker.  In a second step, the maleimide was activated and 
reacted to the cysteine tag of shMFEm-Cys. SEC purified the resulting FX-shMFEm-
Cys conjugate and ELISA confirmed the presence of shMFEm-Cys. 
 
Even though the attachment and purification were proven successful, the ELISA 
revealed a less efficient overall conjugation. Since for Ferucarbotran this required a 
two-step conjugation, substantially more particles were lost through the buffer 
exchanges and handling. Additionally, as a chemical reaction is never 100% efficient, 
there was a considerably lower amount of linker attached to nanoparticles and 
consequently much less scFv. Therefore, cyanogen bromide conjugation was put 
forward to functionalize Ferucarbotran with shMFEm and shNFEm for targeted 
hyperthermia in vivo. 
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4.5 Summary 
The aim of this chapter was to establish a conjugation method to attach scFv antibody 
fragments to Ferucarbotran and characterize the resulting conjugates.  
 
After showing that carbodiimide chemistry destabilized the particles, cyanogen 
bromide conjugation proved to be a suitable method to functionalise Ferucarbotran. 
 
FX-scFv conjugates were purified by size exclusion chromatography and their 
immunoreactivity analysed by quartz crystal microbalance. QCM provided closer 
evaluation of the binding affinity of the attached scFv confirming the targeting 
potential of FX-scFv. 
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Chapter 5 
 
 
 
 
 
 
 
 
 
 
 
 
 
5 Antibody Targeted Magnetic 
Nanoparticle Hyperthermia in vivo 
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5.1 Introduction 
The work in the previous chapters demonstrated the superior in vitro heating potential 
of Ferucarbotran and established that it can be successfully functionalised with scFv 
antibody fragments to enable targeting. The aim of this chapter was to investigate 
whether these findings could be applied in vivo. 
 
When in vitro results are taken to in vivo application, a number of fresh variables are 
introduced. Since tumours are heterogeneous tissues often containing areas of 
necrosis and/or hypoxia, particle distribution within the tumour and possible cooling 
through blood vessels affect the treatment potential of the nanoparticles applied. 
 
Therefore the first experiment was set up to determine Ferucarbotran’s (FX) heating 
potential in vivo. A high and low concentration of FX was injected into SW1222, 
human colorectal carcinoma cell line, xenografts subjected to an AMF. During the 
experiment the tumour and body temperature were monitored. Post-mortem particle 
distribution within the tumour and apoptosis were assessed.  
 
This experiment highlighted the importance of tumour architecture and the need to 
find a method to keep the nanoparticles within the tumour. So, in a second 
experiment particle retention and distribution in different tumour types were 
investigated before, in a third experiment, non-targeted nanoparticle conjugates (FX-
shNFEm) were compared with targeted nanoparticle conjugates (FX-shMFEm). 
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5.2 Objectives 
The objectives of the research described in this chapter were to: 
1. Determine heating potential of Ferucarbotran in vivo 
2. Investigate nanoparticle distribution within in vivo xenograft models of human 
tumours  
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5.3 Results 
5.3.1 Non-Targeted Magnetic Nanoparticle Hyperthermia in vivo 
Ferucarbotran demonstrated a superior heating potential in vitro. Thus, the purpose of 
this experiment was to understand how the in vitro heating potential of Ferucarbotran 
and the second best heating particle fM-DX 100 translates in vivo on a macroscopic 
level. Other parameters, like particle distribution within the tumour as well induction of 
apoptosis, were also investigated. 
 
MF1 nude mice were induced with SW1222 xenografts and separated into two groups 
of three, one treated with FX and the other one with fM-DX 100. In each group, two 
mice were injected with a ‘high dose’ of nanoparticles (2 mg Fe per tumour) injected 
iT, but only one was treated with the AMF for 20 min. The third mouse received iT a 
‘low dose’ of nanoparticles (0.5 mg Fe per tumour) and was also subjected to the 
AMF. Additionally, a control mouse was grown, injected with saline only, but was not 
treated with AMF.  
 
 
Fig. 5.1 Experimental set-up for non-targeted magnetic nanoparticle hyperthermia in vivo 
consisting of the MACH system (not in the picture) with an external copper coil, a water 
cooling system, isofluorane as anesthetic and a thermal imaging camera. 
 
Water cooling system 
Thermal imaging 
camera 
Isofluorane 
Power supply 
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The mice were anaesthetised during the procedure and a thermal imaging camera 
monitored the temperature changes in the tumour. The camera faced the backside of 
the mouse surrounded by the copper coil of the MACH system as shown in Fig. 5.1. 
 
5.3.1.1 Thermal Imaging  
The thermal imaging pictures in Fig. 5.2 taken from the mice injected with FX, confirm 
an immediate temperature increase in the tumour in the presence of the alternating 
magnetic field (AMF), in the tumour treated with the high dose and in the tumour 
treated with the low dose. 
 
After 20 min, the temperature in the tumour treated with 2 mg FX was 7.2 °C above 
the average body surface temperature of the mouse. In the tumour injected with the 
low dose of 0.5 mg FX, the temperature showed a 5.8 °C increase. 
 
Fig. 5.2 Thermal imaging pictures of two SW1222 xenografts injected with FX inside the 
MACH system after 1 min and 20 min treatment with AMF. The tumour (indicated by the 
arrow) received 2 mg FX iT and showed a surface temperature increase of 7.2 °C after  
20 min, while the second tumour (presented in the bottom row) received 0.5 mg FX iT 
displayed a surface temperature increase of 5.8 °C.  
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In addition, to the thermal imaging pictures taken of both mice treated with FX 
combined with the AMF, a temperature probe was inserted into the rectum in order to 
monitor the body temperature. 
 
 
Fig. 5.3 Progression of tumour and body temperature during the treatment inside the MACH 
system of a mouse injected with 2 mg FX and subjected to AMF. ΔT represents the 
temperature difference between the averaged body temperature and the averaged tumour 
temperature. 
 
The temperature changes in Fig. 5.3, showed body and tumour temperatures of the 2 
mg FX mouse, indicating a sharp temperature increase in the tumour area during the 
first minute followed by a slight decrease over the duration of the treatment. 
Interestingly, tumour and body temperature decreased at the same rate.  
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In contrast, the temperature measurements of 0.5 mg FX mouse (Fig. 5.4) revealed, 
after an initial temperature increase within the first minute, an overall rise of the 
temperature in the tumour area as well as the body surface till the end of the 
treatment. 
 
 
Fig. 5.4 Progression of tumour and body temperature during the treatment inside the MACH 
system of a mouse injected with 0.5 mg Ferucarbotran and subjected to AMF. ΔT represents 
the temperature difference between the averaged body temperature and the averaged tumour 
temperature. 
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The thermal imaging pictures from the mice treated with fM-DX 100 in Fig. 5.5 
showed a temperature increase of 4.7 °C in the mouse treated with the high dose and 
1.4 °C with the low dose in the tumour area. 
 
 
Fig. 5.5 Thermal imaging pictures of two SW1222 xenografts injected with fM-DX 100 inside 
the MACH system after 1 min and 20 min treatment with AMF. The tumour (indicated by the 
arrow in the top row) received 2 mg fM-DX 100 iT and showed a surface temperature increase 
of  
4.7 °C after 20 min, while the second tumour (presented in the bottom row) received 0.5 mg 
fM-DX 100 iT displayed a surface temperature increase of 1.4 °C.  
 
Independently of the temperature changes in the tumour regions observed in all mice 
treated, the body temperature dropped after anaesthesia and further during treatment 
indicating the need for a heating supply for consequent hyperthermia experiments 
(eg. through cooling the copper coil of the MACH system to 37 °C instead of 20 °C 
used in this experiment.) 
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5.3.1.2 Histology 
After the magnetic nanoparticle hyperthermia the tumours were excised, processed, 
and cut for further analysis. The tissue sections where then stained with Prussian 
blue to localise the particles in the tumour and cleaved caspase 3 to visualise 
apoptosis. 
 
 
Fig. 5.6 Histology results of tumours treated with Ferucarbotran (FX) with and without the 
presence of the AMF. The tumours were stained with Prussian Blue to reveal the location of 
the particles (blue), as well as immunohistochemistry with a cleaved caspase 3 antibody to 
visualise apoptosis (brown) in the control tumour. In the particle treated tumours apoptosis 
could not be distinguished from the nanoparticles, due to their brown colour, when unstained. 
 
In the Ferucarbotran treated tumours, shown in Fig. 5.6, no particles were found in 
tumours that had received no AMF treatment. In the tumours subjected to the AMF, 
particles were mainly located in the stroma surrounding the tumour, rather than the 
center of the tumour. This suggested that the temperature increase observed through 
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thermal imaging was indeed a reflection of the heating achieved by the 
Ferucarbotran. 
 
 
Fig. 5.7 Histology results of tumours treated with fM-DX 100 with and without the presence of 
the AMF. The tumours were stained with Prussian Blue to reveal the location of the particles 
(blue), as well as immunohistochemistry with a cleaved caspase 3 antibody to visualise 
apoptosis (brown) in the control tumour. In the particle treated tumours apoptosis could not be 
distinguished from the nanoparticles, due to their brown colour, when unstained. 
 
Similarily to the tumours injected with Ferucarbotran, in the tumours treated with fM-
DX 100, the majority of particles were found in the tumours subjected to the AMF 
(seen in Fig. 5.7). While no particles could be located within the tumour centers, the 
majority was found in the tissue surrounding the tumours. This suggested that, 
immediately after injection, the particles, forced by the interstitial pressure, followed 
the needle out of the tumour.  
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Unfortunately, the cleaved caspase 3 staining only indicated apoptosis in the control 
tumour, as in the particle treated tumours, due to the brown colour of the unstained 
particles, no distinction between apoptosis and nanoparticles could be made. 
 
 
5.3.2 Identifying a Suitable Tumour Model for Magnetic Nanoparticle 
Hyperthermia in vivo 
In the previous experiment, SW1222 xenografts were chosen for their homogenous 
tumour growth without or with small areas of apoptosis in order to observe possible 
apoptosis caused by the heating particles. However, the results unfortunately 
suggested a ‘leak’ of the particles into the tissue surrounding the tumour, possibly due 
to high interstitial pressure. Hence, a suitable model and technique had to be found to 
keep the nanoparticles within the tumour.  
 
Therefore, in this experiment six MF1 nude mice were induced with three different 
tumour cell lines: SW1222, human colorectal carcinoma; Capan-1, human pancreatic 
adenocarcinoma and LS174T, human colorectal adenocarcinoma. Consequently, the 
tumours were injected using the technique previously described by Giustini et al. 
(Giustini, Ivkov et al. 2011).  The nanoparticle suspension was injected iT under 
anaesthesia over the course of 30 sec, keeping the needle in place for another 5 min 
in order to optimize particle distribution within the tumour.  
 
Afterwards the mice were left to recover and sacrificed 25 min after withdrawal of the 
needle. The tumours were excised, processed, and stained with Prussian blue and 
haematoxylin and eosin (H&E) for further analysis. 
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Fig. 5.8 Histology results of different xenograft tumours (SW1222 – A and B; Capan-1 – C and 
D; LS174T – E and F) injected with FX. The tumours were stained with Prussian blue to 
enable location of the nanoparticles (blue) and H&E visualise tumour architecture. Tumour 
sizes were different, however the magnification of the staining was kept constant at x2.5. 
 
Histology (Fig. 5.8) revealed an almost even distribution of particles within Capan-1 
and LS174T xenografts, however no improvement was observed within the SW1222 
tumours compared to the first in vivo experiment (see section: 5.3.1). Encouragingly, 
as H&E, revealed the tumour architecture, indicated, particles penetrated deeper into 
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the tumour and substantially more Ferucarbotran was found within the tumour, rather 
than its surrounding stroma.  
 
To investigate the particle distribution throughout the tumour in more detail, the 
second LS174T xenograft (see F in Fig. 5.8) was completely sectioned as shown in 
Fig. 5.9. 
 
 
Fig. 5.9 Histology results of a fully sliced LS174T xenograft. The tumours were stained with 
Prussian blue to enable location of the nanoparticles (blue) and H&E to visualise tumour 
architecture.  
 
Within the slices 1-3 of the second LS174T xenograft (Fig. 5.9), the particles seemed 
to penetrate major areas of the tumour, however, the consecutive slices 4-6, showed 
that the particle distribution in the lower half of the tumour was less optimal. 
Nevertheless, the LS174T xenograft appeared to be the most promising tumour 
model for a targeted nanoparticle injection approach. 
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5.3.3 Intra-tumoural Distribution of Antibody Targeted Magnetic Nanoparticle 
Hyperthermia 
For this experiment FX nanoparticles were conjugated with either shMFEm or 
shNFEm through cyanogen bromide conjugation, purified and characterised as 
described in Chapter 4.  Consequently, LS174T xenografts were raised in six MF1 
nude mice. The mice were divided into two groups of three and under anaesthesia 
injected with either FX-shMFEm or FX-shNFEm using the technique described in 
5.3.2. Subsequently, two mice of each group were left to recover for 55 min before 
they were sacrificed and tumours excised. One mouse of each group was subjected 
to the AMF for 25 min.  During the hyperthermia, the thermal imaging camera 
monitored treatment the surface temperature of the mouse. Afterwards, the mouse 
was left to recover for 30 min, sacrificed and the tumour excised.  The tumours were 
processed, put into paraffin and stained with Prussian blue and H&E for further 
analysis. 
 
Fig. 5.10 Thermal imaging pictures of tumours injected with FX-shMFEm and FX-shNFEm 
inside the MACH system after 1 min and 25 min treatment with AMF. The tumour shown 
within the yellow elipse received FX-shMFEm (3 mg Fe/cm3 tumour) iT and showed a surface 
temperature increase of 0.6 °C after 25 min, while the second tumour (presented in the bottom 
row) received equivalent amount of FX-shNFEm iT displayed a surface temperature increase 
of 4.5 °C.  
 
Thermal imaging results showed a minor increase (less than 1 °C) in surface 
temperature of the tumour treated with FX-shMFEm as shown in Fig. 5.10, but a 
End – 25 min AMF Begin – 1 min AMF 
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FE
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ΔT = 4.5 °C 
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considerable temperature increase (more than 4 °C) in the non-targeted control 
tumour treated with FX-shNFEm. 
 
 
Fig. 5.11 Histology results of different tumours injected with FX-shMFEm and FX-shNFEm 
conjugates. Tumours A and D were subjected to the AMF for 25 min, while tumours B, C, E 
and F received no treatment. The tumours were stained with Prussian blue to enable location 
of the nanoparticles (blue) and H&E to visualise tumour architecture. Tumour sizes were 
different, however the magnification of the staining was kept constant at x2.5. 
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Histological analysis of the tumours (Fig. 5.11) treated with the AMF revealed that 
only a small amount of FX-shMFEm conjugates had stayed in the tumour, while no 
FX-shNFEm conjugates were found within the tumour only in the surrounding tissue. 
The control tumours, which were not subjected to the AMF showed a similar picture.  
 
Interestingly, even though in both cases, tumours were treated with targeted and non-
targeted nanoparticle conjugates, most particles were found in the periphery of the 
tumours, it seemed as if more FX-shMFEm conjugates stayed within the tumour 
tissue than its FX-shNFEm counterpart. 
 
 
5.4 Discussion 
The work presented in this chapter examined the heating potential of Ferucarbotran in 
vivo. It also investigated the localisation of nanoparticles within the tumour and further 
examined the effects of targeting on the intratumoural distribution of Ferucarbotran. 
 
Ferucarbotran demonstrated a superior heating potential in vitro. So the first 
experiment evaluated how this potential translates in vivo. Using a ‘high dose’ (2 mg 
Fe per tumour) or a ‘low dose’ (0.5 mg Fe per tumour), nanoparticles were injected iT 
into SW1222 xenograft model subjected to an alternating magnetic field (AMF) for 20 
min. Afterwards, the tumours were excised, processed, and cut for further analysis.  
 
Thermal imaging results of the surface of the tumour treated with 2 mg Ferucarbotran 
showed a temperature increase in the tumour area of 7.2 °C. Interestingly, thermal 
imaging of another tumour treated with 0.5 mg Ferucarbotran still demonstrated a 
difference between start and end temperature of 5.8 °C. Staining with Prussian blue 
of the excised tumours provided a possible explanation. While most of the particles of 
the ‘low dose’ stayed within the tumour and its rim, the majority of particles in the 
tumour treated with the ‘high dose’ leaked into the surrounding tissue.  Remarkably, 
Prussian blue staining also revealed that almost no particles stayed in the tumours 
injected with nanoparticles not treated with the AMF. Johannsen et al. acquired 
similar results, when they examined the feasibility of magnetic fluid hyperthermia 
treatment of prostate cancer (Johannsen, Jordan et al. 2004).  
 
Since in the first experiment it looked like the particles left the tumour with the 
removal of the needle after iT injection, a new injection technique, as well as different 
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tumour cell lines was evaluated. Therefore three different CEA expressing xenograft 
tumour types were raised. Additionally to the SW1222, human colorectal carcinoma; 
Capan-1, human pancreatic adenocarcinoma and LS174T, human colorectal 
adenocarcinoma were induced.  The nanoparticle suspension was injected iT over 
the course of 30 sec, while keeping the needle in place for a total of 5 min in order to 
optimize particle distribution within the tumour, as described by Giustini et al. 
(Giustini, Ivkov et al. 2011) 
 
Histology of the excised tumours showed again a leakage of particles into the 
surrounding tissue in the SW1222 xenograft. In Capan-1 and LS174T tumours 
particles were mainly found in the tumour centres.  To gain a better understanding of 
the particle distribution, the second LS174T tumour was sliced up completely, 
revealing that the nanoparticles were able to penetrate most of the tumour. Based on 
these results it was decided to move forward using Giustini’s injection technique and 
LS174T xenografts.  So, for the next experiment LS174T xenografts were raised in 
six MF1 nude mice. The mice were divided into two groups of three and injected with 
either FX-shMFEm or FX-shNFEm. Subsequently, one mouse of each group was 
subjected to the AMF for 25 min.  
 
During the hyperthermia treatment, the thermal imaging camera monitored the 
surface temperature of the mouse. Afterwards, the mouse was left to recover for 30 
min, sacrificed and the tumour excised.  The tumours were processed, put into 
paraffin, and stained with Prussian blue and H&E for further analysis. 
 
Thermal imaging results showed a minor increase (less than 1 °C) in surface 
temperature of the tumour treated with FX-shMFEm, but a considerable temperature 
increase (more than 4 °C) in the non-targeted control tumour treated with FX-
shNFEm.  However, pathology revealed in both cases, tumours treated with targeted 
and non-targeted nanoparticle conjugates, most particles were found in the periphery 
of the tumours; it seemed as if more FX-shMFEm conjugates stayed within the 
tumour tissue than its FX-shNFEm counter parts. 
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5.5 Summary 
The aim of the work in this chapter was to examine the in vitro heating potential of 
Ferucarbotran in a xenograft tumour model. Even though this Ferucarbotran’s 
hyperthermia potential was confirmed, histology showed that the majority of the 
particle did not stay within the tumour and migrated to the stroma surrounding the 
tumour. So, consequently, different tumour models and a new injection method were 
tested.  A LS174T xenograft was deemed suitable, injected with FX-shMFEm and FX-
shNFEm, antibody nanoparticle conjugates and subjected to AMF.  
 
The results supported the hypothesis of a therapeutic potential for targeted magnetic 
nanoparticle hyperthermia, but also indicate challenges that have to be addressed to 
enable clinical application of this treatment modality. 
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Chapter 6 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
6 Discussion and Conclusion 
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The work in this thesis strategically investigated the hypothesis that targeted 
superparamagnetic iron oxide nanoparticles (SPION) subjected to an alternating 
magnetic field have the potential to induce localised hyperthermia in cancer therapy.  
 
To test this hypothesis, an array of commercially available iron oxide nanoparticles 
were thoroughly characterised and examined for their hyperthermia potential. The 
best candidate, Ferucarbotran, was then functionalised with scFv antibody fragments 
specifically targeting carcinoembryonic antigen (CEA). Appropriate conjugation and 
purification techniques were applied, evaluated and optimised; with QCM, a novel 
way of characterizing FX-scFv conjugates was explored yielding important 
information about their functionality. The superior in vitro heating capability of 
Ferucarbotran was tested and confirmed in vivo, before the therapeutic potential of 
non-targeted and targeted SPION was examined.  The results supported the 
hypothesis of a therapeutic potential for targeted magnetic nanoparticle hyperthermia, 
but also highlighted challenges, which need to be addressed in order to reach its full 
clinical potential. 
 
My work has highlighted the need for characterisation, in the field of biomedical 
applications of nanoparticles, as deviations from the manufacturer’s specifications 
occur. It is essential to know the properties the nanoparticles possess that we use, 
not only for our research, but also for the comparability of results within the research 
community. 
 
A difference in the hydrodynamic diameter (see section: 1.1.1) might change the 
nanoparticles’ route of clearance and therefore its blood half life. For hyperthermia 
application the consequences might be even more severe, as the combination of 
hydrodynamic diameter and dispersity, core diameter and composition of the 
nanoparticle suspension will define its heating potential (Krishnan 2010; Ortega 
2012). 
 
Furthermore, in the literature particles are often described as ‘stable in water’, but as 
long as their stability is not shown under physiological conditions, it’s impossible to 
draw valid conclusions. Moreover, it has been shown that aggregation negatively 
impacts the heating potential of nanoparticles (Dutz, Clement et al. 2009).  
 
After thorough property analysis, Ferucarbotran was found to be the most suitable 
magnetic nanoparticle for a potential therapeutic hyperthermia application, due to its 
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superior heating capability. Consequently, Ferucarbotran, also known as 
unformulated MRI contrast agent Resovist®, was functionalised with the anti-CEA 
scFv antibody fragment shMFEm, and it’s non-binding variant shNFEm, via cyanogen 
bromide conjugation (see section: 4.3.1.4). However, by adapting quartz crystal 
microbalance for the characterization of the FX-shMFEm conjugate, it enabled the 
first time real time visualisation of the interaction between the conjugate and its 
cognate antigen (see section: 4.3.3.2), delivering important information on the 
potential behaviour of the magnetic nanoparticle conjugate in vivo.  
 
The resulting binding kinectics indicated a slightly slower association rate and an 
almost twice as fast dissociation rate in comparison to results of the pure shMFEm. 
These results suggested that some of the scFv molecules might only be partially 
accessible due to particle shape, but also physical hindrance due to the flexible 
dextran matrix potentially covering the shMFEm. This motivated not only a look into 
more stealth coatings, such as polystyrene or PEG, but also site-specific attachment 
(see section: 4.3.4.2), where conjugation is facilitated through a specific target 
residue (eg. cysteine) to create a single connection, an interesting technique ensuring 
the functionality of the attached targeting moiety. 
 
The in vivo translation of the superior in vitro heating potential of unconjugated 
Ferucarbotran showed a substaintial temperature increase in the tumour area during 
treatment; however, the histological analysis revealed that even though the particles 
were directly injected into the tumour, most nanoparticles leaked into the surrounding 
tissue (see section: 5.3.1). This highlighted one of the biggest challenges in magnetic 
nanoparticle hyperthermia: delivery.  
 
Therefore, in a second experiment, different tumour types, as well as a new injection 
method were tested (see section: 5.3.2). By injecting the nanoparticle suspension iT 
over the course of 30 sec, while keeping the needle in place for a total of 5 min, as 
described by Giustini et al. (Giustini, Ivkov et al. 2011), the particle distribution was 
optimised, enabling direct comparison of the therapeutic potential of targeted FX-
shMFEm and the non-targeted control FX-shNFEm (see section: 5.3.3).  
 
While only a minor temperature (less than 1 °C) increase was observed in the tumour 
treated with FX-shMFEm, a considerable temperature increase (more than 4 °C) was 
observed in the tumour treated with the FX-shNFEm conjugates. Pathology revealed 
that even though most particles were found in the surrounding tissue, more FX-
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shMFEm conjugates stayed within the tumour tissue than its FX-shNFEm counter 
parts supporting the hypothesis of a therapeutical potential for targeted magnetic 
nanoparticle hyperthermia. 
 
However, in order for magnetic nanoparticle hyperthermia to reach its full clinical 
potential, a number of challenges, besides the need for targeting, have to be 
addressed, such as the missing consensus within the field on what magnetic fields 
can be applied to the human body.  
 
While a number of research groups (Andra, d'Ambly et al. 1999) are still using 
magnetic field strengths up to 10 kA/m (Brezovich 1988) others apply fields up to  
90 kA/m, (Bordelon, Cornejo et al. 2011) which might induce eddy currents in the 
tissue and are therefore not safe for in vivo application (Hergt, Dutz et al. 2006; Hergt 
and Dutz 2007).  
 
There is also a critical need to understand the biological effects of magnetic 
nanoparticle hyperthermia. How are magnetic particles affecting the targeted cells? 
How can the synergy between chemo and/or radiation therapy with hyperthermia be 
improved through the application of magnetic nanoparticles? Does hyperthermia 
really activate the immune system to induce anti-tumour immogenicity, as suggested 
by Ito et al. (Ito, Shinkai et al. 2001; Ito, Shinkai et al. 2003; Torigoe, Tamura et al. 
2009)? 
 
The beauty of using magnetic nanoparticles is that we can design and engineer them 
to meet the requirements of a clinical application. Especially, in hyperthermia, to have 
the ability to use a magnetic field, instead of infrared light or radiation (Cherukuri, 
Glazer et al. 2010), to achieve an increase in temperature, is a major advantage as 
the human body is almost transparent without limitation of maximum penetration 
depths. 
 
In conclusion I have established important parameters for magnetic nanoparticles in 
vivo and provided a novel approach enabling the better characterization of the binding 
kinetics of nanoparticle-antibody conjugates. This thesis will provide an important 
guide into bringing targeted magnetic nanoparticle hyperthermia closer to the clinic. 
 117 
Chapter 7 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
7 Future Challenges 
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In order to take the work presented in this thesis forward, next particles with a more 
stealth coating, such as polyethylene glycol (PEG), should be evaluated for their 
therapeutic potential for a targeted hyperthermia approach.  This should include an 
extensive property analysis of the magnetic nanoparticles, examining hydrodynamic 
diameter, zeta potential, core diameter, iron content, as well as magnetic properties 
and heating potentials.  
 
In this regard, in addition to standard techniques, such as dynamic light scattering to 
determine the hydrodynamic diameter, other methods like nanoparticle tracking 
analysis (NTA) should also be explored. In contrast to DLS, where fluctuations of the 
intensity of the scattered light caused by a small number of particles in the path of a 
laser beam are measured, NTA tracks individual particles and determines their 
hydrodynamic size through their Brownian motion resulting not only in higher number 
of measurements, but also providing a more complete picture of the size distribution 
within a nanoparticle suspension. 
 
Additionally, in order to assure the functionality of the scFv antibody fragments after 
attachment, one-step site-specific attachment techniques should be further explored 
and compared to the more commonly used random conjugation chemistries, such as 
carbodiimide chemistry, using quartz crystal microbalance.  
 
Further work also includes the in vivo evaluation of the antibody targeted and non-
targeted conjugates through direct intratumoural injection. However, the final goal will 
be systemic delivery of actively targeted magnetic nanoparticles for hyperthermia 
application. 
 
On a wider scale, in order to advance the field of magnetic particle hyperthermia, the 
mechanisms of magnetic nanoparticle hyperthermia have to be better understood.  It 
still remains a mystery whether magnetic nanoparticle hyperthermia is a local heating 
phenomenon, or a bulk-heating phenomenon. On the one hand, theoretical modelling 
by Rabin (Rabin 2002) implies that the energy dissipation by nanoscale heating 
should have a negligible effect, while experimental data by Huang et al. (Huang, 
Delikanli et al. 2010) indicates otherwise. Huang et al. specifically targeted magnetic 
nanoparticles to activate the temperature sensitive ion channel TRPV1 through the 
application of an alternating magnetic field. More interestingly, by using the 
temperature dependence of the fluorescence intensity of fluorophores attached to the 
nanoparticles and free in suspension, an immediate decrease in fluorescence of the 
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fluorophore on the particle was reported with the application of the alternating 
magnetic field. However, the intensity of the free fluorophore stayed constant, 
indicating local heating of the particles. If this local heating phenomenon in magnetic 
nanoparticles is confirmed, it would transform the field magnetic nanoparticle 
hyperthermia, enabling a more targeted therapy and expanding its range of 
applications.  
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Table 2.1: Solutions for dynamic light scattering and zeta potential measurement 
Buffers Formula 
dH2O 500 ml distilled water sterile filtered. 
5 mM Sodium chloride Dissolve 0.15 g sodium chloride in  500 ml dH2O. Filter to sterilize. 
PBS Add 50 ml 10x PBS to 450 ml dH2O 
 
 
Table 2.2: Solutions for SPION-scFv carbodiimide conjugation 
Buffers Formula 
0.1 M Sodium phosphate buffer pH 7.2 
Dissolve 0.44 g monosodium phosphate 
and 1.83 g disodium phosphate in 90 ml 
dH2O. Adjust pH and bring up to 100 ml 
by adding dH2O. Filter to sterilize. 
EDC/NHS Activation buffer 
Add 2.5 mg EDC and 1.25 mg NHS to 
200 µl 0.1 M sodium phosphate buffer. 
Use immediately. 
50 mM Glycine 
Dissolve 36 mg glycine in 10 ml 0.1 M 
sodium phosphate buffer pH 8.5. Filter to 
sterilize. 
 
 
Table 2.3: Solutions for SPION-scFv cyanogen bromide conjugation 
Buffers Formula 
50 mM Sodium borate buffer pH 8.5 
Dissolve 4.77 g sodium tetraborate 
decahydrate in 200 ml dH2O, adjust the 
pH with HCl and fill up to 250ml volume. 
Filter to sterilize. 
Cyanogen bromide 5 M cyanogen bromide in acetonitrile (Sigma) 
PBS Add 10 ml 10x PBS to 90 ml dH2O 
50 mM Glycine 
Dissolve 36 mg glycine in 10 ml 0.1 M 
sodium phosphate buffer pH 8.5. Filter to 
sterilize. 
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Table 2.4: Solutions for SPION-scFv site-specific conjugation 
Buffers Formula 
50 mM Sodium borate buffer pH 8.5 
Dissolve 4.77 g sodium tetraborate 
decahydrate in 200 ml dH2O, adjust the 
pH with HCl and fill up to 250ml volume. 
Filter to sterilize. 
50 mM Sodium borate buffer pH 7 
Dissolve 4.77 g sodium tetraborate 
decahydrate in 200 ml dH2O, adjust the 
pH with HCl and fill up to 250ml volume. 
Filter to sterilize. 
Stabilization buffer Dissolve 5 M sodium cyanoborohydride in 1 M NaOH.  
50 mM Glycine 
Dissolve 36 mg glycine in 10 ml 50 mM 
sodium borate buffer pH 8.5. Filter to 
sterilize. 
50 mM Cysteine 
Dissolve 0.6 g cysteine in 10 ml 50 mM 
sodium borate buffer pH 7. Filter to 
sterilize. 
 
 
Table 2.5: Solutions for SDS-PAGE 
Buffers Formula 
Running Buffer Stock (10X) Dissolve 30 g Trizma
® base and 144.2 g 
glycine in 1 l dH2O. 
Running Buffer Dilute 100 ml running buffer stock with 900 ml dH2O. 
4X Reducing Buffer 
Make 1.25 mM Tris-HCl, pH 6.8 solution 
in dH2O; add 20% glycerol; 4% β-
mercaptoethanol; 0.1% bromophenol 
blue and 0.1% SDS. All percentages w/v. 
4X Non-reducing Buffer 
Make 1.25 mM Tris-HCl, pH 6.8 solution 
in dH2O; add 20% glycerol; 0.1% 
bromophenol blue and 0.1% SDS. All 
percentages w/v. 
Coomassie gel stain  
Mix 0.1 g coomassie blue R-250 with 100 
ml methanol, 20 ml glacial acetic acid 
and 80 ml dH2O. 
Gel de-stain solution For 2.5 l: mix 1.25 l methanol with 1 l dH2O and 250 ml glacial acetic acid. 
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Table 2.6: Solutions for Western Blot 
Buffers Formula 
Transfer Buffer Stock (10X) Dissolve 30 g Trizma
® base, 144.2 g 
glycine and 10 g SDS in 1 l dH2O. 
Transfer Buffer Dilute 100 ml transfer buffer stock with 700 ml dH2O and 200 ml methanol. 
5% Milk Dissolve 2.5 g milk powder (Marvel) in  50 ml PBS. 
 
 
Table 2.7: Solutions for casting a native gel 
Buffers Formula 
1 M Tris pH 6.8 
Dissolve 30.3 g Trizma® base in 175 ml 
dH2O and adjust the pH with 
concentrated HCl (37.2%). Bring up to 
final volume by adding dH2O accordingly. 
1 M Tris pH 8.8 
Dissolve 30.3 g Trizma® base in 175 ml 
dH2O and adjust the pH with 
concentrated 1 M NaOH. Bring up to final 
volume by adding dH2O accordingly. 
10% APS 
Dissolve 1 g ammonium persulfate in 10 
ml dH2O. Prepare 100 µl aliquots and 
store at -20 °C 
10% SDS 
Add 25 g sodium dodecyl sulfate (SDS) 
to 220 ml dH2O. Place the container into 
water bath at 65 °C to dissolve the SDS. 
After cooling add dH2O for a final volume 
of 250 ml. 
 
 
Table 2.8: Solutions for quartz crystal microbalance 
Buffers Formula 
PBS Dissolve PBS dry powder in 1 l dH2O. 
PBS-T Take 1 l PBS and add 0.1% Tween-20. 
BSA Dissolve 1 mg bovine serum albumin in  1 ml PBS 
Glycine pH 3 Add 75 mg glycine to 10 ml dH2O and adjust pH to 3. 
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Table 2.9: Solutions for tissue culture 
Buffers Formula 
Culture Medium for Capan-1 To 500 ml Iscove’s Modified Dulbecco’s Media (ATCC) add 100 ml FCS 
Culture Medium  
for LS174T, A375M and SW1222 
To 500 ml MEM with Earle’s Salts add  
5 ml 100x L-Glutamine, 50 ml FCS and  
5 ml 100x NEAA 
Trypsin 1x Trypsin (0.05%) w/ EDTA 
PBS Sterile 1x PBS  
Freezing medium Culture medium with 5% DMSO 
 
 
Table 2.10: Solutions for tissue culture 
Buffers Formula 
Fixing buffer 4% paraformaldehyde in dH2O 
50 mM Glycine Dissolve 0.36 g glycine in 100 ml PBS 
 
 
Table 2.11: Solutions for Prussian blue staining 
Buffers Formula 
Reaction mix 
Dissolve 4 g potassium ferrocyanide in 
20 ml dH2O and combine with 20 ml 2% 
HCl shortly before use. 
 
All chemicals were purchased from Sigma-Aldrich (St. Louis, MO, USA). All buffers 
were filtered through 0.2 um Nalgene filter (VWR Int., Leicestershire, UK).  
 
The reagents for tissue culture were obtained from PAA Laboratories (Pasching, 
Austria) unless specified. 
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Determining the theoretical maximum energy loss (X”) 
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